


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:28Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406253" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406253</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="c043063578" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><self-uri>pubs.acs.org/jmc</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406253</article-id><article-id pub-id-type="pmcid-ver">PMC12406253.1</article-id><article-id pub-id-type="pmcaid">12406253</article-id><article-id pub-id-type="pmcaiid">12406253</article-id><article-id pub-id-type="pmid">40779719</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.5c00629</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Exploration
of the Neuromodulatory Properties of Fyn
and GSK-3&#946; Kinases Exploiting 7&#8209;Azaindole-Based Inhibitors</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7420642</contrib-id><name name-style="western"><surname>Marotta</surname><given-names initials="G">Giambattista</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6164104</contrib-id><name name-style="western"><surname>Massenzio</surname><given-names initials="F">Francesca</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7540551</contrib-id><name name-style="western"><surname>Ortega</surname><given-names initials="J">Jose</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3172649</contrib-id><name name-style="western"><surname>Russo</surname><given-names initials="D">Debora</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7529839</contrib-id><name name-style="western"><surname>Penna</surname><given-names initials="I">Ilaria</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6577669</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7385-649X</contrib-id><name name-style="western"><surname>Falchi</surname><given-names initials="F">Federico</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7540553</contrib-id><name name-style="western"><surname>Babini</surname><given-names initials="G">Giorgia</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath8" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7540555</contrib-id><name name-style="western"><surname>Petralla</surname><given-names initials="S">Sabrina</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath9" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1062123</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2623-306X</contrib-id><name name-style="western"><surname>Scarpelli</surname><given-names initials="R">Rita</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath10" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7540562</contrib-id><name name-style="western"><surname>Roggiolani</surname><given-names initials="E">Elena</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath11" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">970623</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3894-961X</contrib-id><name name-style="western"><surname>Fricker</surname><given-names initials="G">Gert</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath12" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">370666</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3750-2728</contrib-id><name name-style="western"><surname>Rosini</surname><given-names initials="M">Michela</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath13" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7540558</contrib-id><name name-style="western"><surname>Cavalli</surname><given-names initials="A">Andrea</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath14" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">4983334</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0330-482X</contrib-id><name name-style="western"><surname>Monti</surname><given-names initials="B">Barbara</given-names></name><xref rid="aff2" ref-type="aff"/><xref rid="aff7" ref-type="aff"/></contrib><contrib id="ath15" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">368808</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4905-0944</contrib-id><name name-style="western"><surname>Minarini</surname><given-names initials="A">Anna</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath16" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">4165093</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0710-4251</contrib-id><name name-style="western"><surname>Basagni</surname><given-names initials="F">Filippo</given-names></name><xref rid="cor2" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Pharmacy and Biotechnology</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">9296</institution-id><institution>Alma Mater
Studiorum&#58872;University of Bologna</institution></institution-wrap>, <addr-line>Via Belmeloro 6</addr-line>, <postal-code>40126</postal-code>
<city>Bologna</city>, <country country="IT">Italy</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">Department
of Pharmacy and Biotechnology</institution>, <institution>Alma Mater
Studiorum&#58872;University of Bologna</institution>, <addr-line>Via Selmi 3</addr-line>, <postal-code>40126</postal-code>
<city>Bologna</city>, <country country="IT">Italy</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">Computational
and Chemical Biology</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">121451</institution-id><institution>Istituto Italiano
di Tecnologia</institution></institution-wrap>, <addr-line>Via Morego 30</addr-line>, <postal-code>16163</postal-code>
<city>Genova</city>, <country country="IT">Italy</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution>D3
Pharma Chemistry, Istituto Italiano di Tecnologia</institution>, <addr-line>via Morego 30</addr-line>, <postal-code>16163</postal-code>
<city>Genova</city>, <country country="IT">Italy</country>
</aff><aff id="aff5">
<label>&#8869;</label>
<institution content-type="dept">Medicinal
Chemistry and Technologies for Drug Discovery and Delivery Facility</institution>, <institution>Istituto Italiano di Tecnologia</institution>, <addr-line>via Morego 30</addr-line>, <postal-code>16163</postal-code>
<city>Genova</city>, <country country="IT">Italy</country>
</aff><aff id="aff6">
<label>#</label>
<institution content-type="dept">Institute
of Pharmacy and Molecular Biotechnology</institution>, <institution>Ruprecht-Karls-University</institution>, <addr-line>Im Neuenheimer Feld 364</addr-line>, <postal-code>69120</postal-code>
<city>Heidelberg</city>, <country country="DE">Germany</country>
</aff><aff id="aff7">
<label>&#182;</label>
<institution>IRCCS
Istituto delle Scienze Neurologiche di Bologna</institution>, <addr-line>Via Altura 3</addr-line>, <postal-code>40139</postal-code>
<city>Bologna</city>, <country country="IT">Italy</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>anna.minarini@unibo.it</email>. Phone: <phone>+39 051 2099709</phone>.</corresp><corresp id="cor2"><label>*</label>Email: <email>filippo.basagni2@unibo.it</email>. Phone: <phone>+39 051 2099744</phone>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>08</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><volume>68</volume><issue>16</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>17130</fpage><lpage>17154</lpage><history><date date-type="received"><day>04</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>25</day><month>7</month><year>2025</year></date><date date-type="online"><day>08</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-08"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-08">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jm5c00629.pdf"/><abstract><p>The lack of efficient
treatments and reliable biomarkers
for neurodegenerative
diseases requires the development of a late-stage powerful therapy.
To this aim, we focused on Fyn and GSK-3&#946; because both kinases
are strictly involved in regulating neurodevelopmental processes,
besides orchestrating neurotoxic aggregates&#8217; deposition and
neuroinflammatory processes development. Based on these premises,
we developed dual kinase inhibitors to verify at the cellular level
the suitability of Fyn and GSK-3&#946; modulation in pursuing the
recovery of neural trophism paired to the activation of a neuroprotective
profile. Starting from the mild inhibitory potency of the 3-aminothiazole-7-azaindole
scaffold, we identified nanomolar dual and selective inhibitors among
the kinases of interest. In-depth biological evaluations were performed
with the best compounds of the series to assess the neuroprotective
and neuromodulatory properties, like enabling neurogenesis or glial
polarization, as well as triggering immunomodulation with different
patterns relating to their inhibitory profile, setting the stage for
potential development of neuroregenerative treatments.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="jm5c00629_0024.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="jm5c00629_0022.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Ministero dell'Universit&#224; e della Ricerca</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100021856</institution-id></institution-wrap></funding-source><award-id>2017MT3993_007</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm5c00629</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm5c00629</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>78a8c81bc0ab44eb19b14cf0687ac9384df004e665f13c4421ceca53ad1e5bd1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>The intricate etiopathology of neurodegenerative
diseases represents
one of the biggest unmet medical needs, which results in a lack of
efficient treatments able to halt the cognitive/motor deterioration.
Impaired neurotransmission systems, as well as neurotoxic aggregates
of misfolded proteins guided by neuroinflammatory processes jointly
contribute to synaptic loss and neuronal death leading to neurodegeneration.<xref rid="ref1" ref-type="bibr"/> The lack of reliable biomarkers for robust early
diagnosis made the available treatments ineffective, as they usually
intervene in already compromised neurodegenerative conditions.<xref rid="ref2" ref-type="bibr"/> Therefore, the chance to step in with potential
treatment able to merge neuromodulatory to neuroprotective properties
could result in amplified therapeutic effect favoring the shift from
neurodegeneration to neuroregeneration.<named-content content-type="bibref-group">
<xref rid="ref3" ref-type="bibr"/>,<xref rid="ref4" ref-type="bibr"/>
</named-content> Particularly,
the pharmacological triggering of neurogenic and neurodevelopmental
processes should contribute to arrest cognitive/motor decline while
preventing neurodegeneration, with the establishment of an induced
neuroprotective defense.</p><p>To this aim, Fyn proto-oncogene kinase
(Fyn) and Glycogen synthase
kinase 3&#946; (GSK-3&#946;) emerged as promising targets for their
multiple involvement in modulating brain physiopathological conditions.
Besides triggering and fostering the formation of neurotoxic aggregates
and the development of inflammatory processes, both kinases are physiologically
involved in synaptic plasticity and glia formation.<xref rid="ref5" ref-type="bibr"/> Fyn is a nonreceptor tyrosine kinase belonging to the Src
family involved in multiple neurodevelopmental processes, such as
promoting myelination, mediating oligodendrocytes differentiation
and maturation, and controlling neuronal migration and synaptic regulation.<xref rid="ref6" ref-type="bibr"/> Fyn dysregulation represents a shared neurotoxic
feature among neurodegenerative disorders.<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>,<xref rid="ref8" ref-type="bibr"/>
</named-content> In
common with GSK-3&#946;, Fyn is one of the most responsible kinases
for amyloid precursor protein (APP) phosphorylation, thus triggering
amyloidogenic cleavage and tau hyperphosphorylation, favoring neurofibrillary
tangles (NFT) deposition.<xref rid="ref9" ref-type="bibr"/> Furthermore,
Fyn acts as an essential cellular player in boosting amyloid beta
peptide (A&#946;) and &#945;-synuclein-induced neurotoxic cascade,
while its persistent upregulation during neuroinflammation paired
with its physiological expression in microglia and astrocytes make
it a major conduit for fostering inflammatory processes.<xref rid="ref10" ref-type="bibr"/> It is therefore not surprising that several
animal models with Fyn ablation reported significantly mitigated A&#946;-induced
mortality, inflammation, NFT reduction, and dopaminergic degeneration.<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>,<xref rid="ref11" ref-type="bibr"/>
</named-content>
</p><p>GSK-3&#946; is a serine/threonine kinase widely expressed
in the
brain and broadly recognized as a valid target to contrast neuroinflammatory
and neurodegenerative processes due to its strict entanglement in
protein dysregulation, with the following neurotoxic aggregates deposition,
or as a pivotal inflammation regulator.<named-content content-type="bibref-group">
<xref rid="ref12" ref-type="bibr"/>,<xref rid="ref13" ref-type="bibr"/>
</named-content> Moreover,
experimental evidence from several studies confirmed the direct involvement
of GSK-3&#946; signaling in neural development and neuronal polarization,
offering prospects for potential GSK-3&#946;-directed neuromodulating
therapies.<xref rid="ref14" ref-type="bibr"/> Specifically, its inactivation
drives neural progenitor proliferation, migration, and differentiation.<xref rid="ref15" ref-type="bibr"/> Furthermore, GSK-3&#946; inhibitors proved
to exert remarkable neuroprotective properties to multiple neurotoxic
insults and anti-inflammatory activities through phosphorylation-mediated
modulation of the different transcription factors or signaling pathways.<xref rid="ref16" ref-type="bibr"/> Notably, GSK-3&#946; has been also identified
as one of Fyn upstream regulators during cellular antioxidant response.<xref rid="ref17" ref-type="bibr"/>
</p><p>Based on these premises, we aimed to combine
the structural features
responsible for Fyn and GSK-3&#946; inhibition in single chemical
entities to potentially merge the neuromodulatory properties with
neuroprotective activities derived from their modulation to validate
a potential synergistic neuroregenerative approach. Albeit several
Fyn or GSK-3&#946; inhibitors have been developed and evaluated for
neurodegenerative diseases treatment, unfortunately translation into
clinical practice has not occured.<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>,<xref rid="ref13" ref-type="bibr"/>,<xref rid="ref18" ref-type="bibr"/>
</named-content> In this study, for the first time dual Fyn/GSK-3&#946;
inhibitors were purposely developed and characterized for their neuromodulatory
properties. To this aim, we started from the 3-aminothiazole-7-azaindole
scaffold, endowed with moderate Fyn and GSK-3&#946; inhibitory potencies,
and following several rounds of structural refinement, we identified
nanomolar dual inhibitors that were then evaluated in suitable bidimensional
(2D) and 3D cell cultures for their neuroprotective and neuromodulatory
activities. Additionally, once the structural features required for
optimal modulation of two kinases within the same class of compounds
were identified, selective Fyn or GSK-3&#946; inhibitors were developed
and exploited in biological investigation to clearly depict the specific
input ascribed to the modulation of the two kinases for the resulting
biological properties.</p></sec><sec id="sec2"><title>Results and Discussion</title><sec id="sec2.1"><title>Structure&#8211;Activity
Relationship</title><p>In this work,
we selected the 3-aminothiazole-7-azaindole core as a suitable starting
point for the identification of potential GSK-3&#946; and Fyn inhibitors.
In preliminary <italic toggle="yes">in vitro</italic> evaluation, compound <bold>I</bold> promisingly inhibited both kinases, albeit with unbalanced
potency toward GSK-3&#946; (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). From these premises, we started a hit-optimization
campaign by systematically modifying the three regions of hit compound <bold>I</bold> (i.e., amino group, thiazole, and azaindole cores) to define
the structural requirements for the optimal inhibition of the target
kinases. First, different aliphatic and aromatic substituents were
introduced on the amino group of thiazole, generating compounds <bold>1</bold>&#8211;<bold>8</bold>. From this series, benzyl derivative <bold>7</bold> emerged as the best one in terms of balanced activity, while
the other members of the series gave a weak inhibition, especially
on Fyn (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). Particularly,
except for <bold>7</bold>, only compound <bold>6</bold> bearing the
phenyl side chain maintained the inhibitory activities of <bold>I</bold>. Therefore, we evaluated a small set of different substituents on
the aromatic core (compounds <bold>9</bold>&#8211;<bold>16</bold>, <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>) without
achieving satisfying balanced inhibitors. To note, only the replacement
of the phenyl ring with <italic toggle="yes">p</italic>-<italic toggle="yes">N,N</italic>-dimethyl
aniline or a <italic toggle="yes">p</italic>-aniline (compounds <bold>15</bold> and <bold>16</bold>, respectively) retained the selective GSK-3&#946;
inhibitory property of <bold>6</bold> and <bold>I</bold>, indicating
that these substituents are better tolerated in this kinase. Afterward,
we selected the more promising benzyl derivative <bold>7</bold> to
explore the amino region. Initially, we focused on benzyl analogues <bold>17</bold>&#8211;<bold>26</bold> (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>) by introducing small functional groups
in ortho-, meta-, and para-positions or by replacing the aromatic
core with <italic toggle="yes">N</italic>-heterocycles (4-pyridine in <bold>27</bold>, 3-chloro-4-pyridine in <bold>28</bold>, 2-pyrimidine in <bold>29</bold>, and 2-pyrazine in <bold>30</bold>, <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). Among the selected substituents, only
the <italic toggle="yes">p</italic>-nitro group (in compound <bold>24</bold>) led
to an improved submicromolar inhibitory profile toward GSK-3&#946;.
Regarding the different heterocycles attached in the side chain, the
location of a nitrogen atom was preferred in the para position as
occurs in compound <bold>27</bold> (GSK-3&#946; IC<sub>50</sub> =
0.28 &#177; 0.07 &#956;M; Fyn IC<sub>50</sub> = 3.48 &#177; 0.68
&#956;M), whose inhibitory potencies were boosted with the insertion
of an ortho-chloro substituent achieving the first double-digit nanomolar
inhibitor of the series (<bold>28</bold>, GSK-3&#946; IC<sub>50</sub> = 0.038 &#177; 0.006 &#956;M; Fyn IC<sub>50</sub> = 0.71 &#177;
0.09 &#956;M). Finally, different modifications were also explored
in the aminomethyl bridge, such as the elongation of the methylene
chain (<bold>31</bold>), the blockage with an amide group (<bold>32</bold>), and capping into a tertiary amine function (<bold>33</bold>),
which totally disrupted Fyn activity while GSK-3&#946; seemed more
tolerant with these modifications, except for amidation (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>).</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>
<italic toggle="yes">In Vitro</italic> Results
of GSK-3<italic toggle="yes">&#946;</italic> and Fyn Inhibition for Compounds <bold>1</bold>&#8211;<bold>33</bold>
<xref rid="t1fn2" ref-type="table-fn"/>
</title></caption><graphic id="GRAPHIC-d14e500-autogenerated" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00629_0017.jpg"/><graphic id="gr17_1" position="float" orientation="portrait" xlink:href="jm5c00629_0018.jpg"/><graphic id="gr17_2" position="float" orientation="portrait" xlink:href="jm5c00629_0019.jpg"/><table-wrap-foot><fn id="t1fn2"><label>a</label><p>Percentages of
inhibition and IC<sub>50</sub> values are reported as a mean value
(&#177;SD) of at least
three independent determinations. For most promising compounds, dose&#8211;response
curves have been performed and IC<sub>50</sub> determined. The percentage
of inhibition at the highest dose tested (100 &#956;M) is shown for
compounds that did not reach a full dose&#8211;response for poor
solubility in assay buffer (marked with *). n.i. = no inhibition.
n.d. = not determined (IC<sub>50</sub> was not calculated for compounds
with a percentage of inhibition lower than 60% at 50 &#956;M).</p></fn></table-wrap-foot></table-wrap><p>Then, we focused on the role of
the 7-azaindole core
in targets
interaction. First, the removal, substitution, or masking of even
one of the nitrogens led to a complete loss of activity toward the
two kinases (compounds <bold>34</bold>&#8211;<bold>37</bold>, <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>), highlighting the
essential role of vicinal H-bonding acceptor&#8211;donor scheme in
positions 1 and 7 for the inhibition. Surprisingly, the insertion
of a bromine atom in position 5 (compound <bold>38</bold>, <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) increased the selectivity
and inhibitory potency on Fyn in the submicromolar range (Fyn IC<sub>50</sub> = 0.55 &#177; 0.02 &#956;M).</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>2</label><caption><title>
<italic toggle="yes">In Vitro</italic> Results
of GSK-3<italic toggle="yes">&#946;</italic> and Fyn Inhibition for Compounds <bold>34&#8211;43</bold>
<xref rid="t2fn1" ref-type="table-fn"/>
</title></caption><graphic id="GRAPHIC-d14e543-autogenerated" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00629_0020.jpg"/><graphic id="gr17" position="float" orientation="portrait" xlink:href="jm5c00629_0021.jpg"/><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Percentages
of inhibition and IC<sub>50</sub> values are reported as a mean value
(&#177;SD) of at least
three independent determinations. For most promising compounds, dose&#8211;response
curves have been performed and IC<sub>50</sub> determined. n.i. =
no inhibition. n.d. = not determined (IC<sub>50</sub> was not calculated
for compounds with a percentage of inhibition lower than 60% at 50
&#956;M).</p></fn></table-wrap-foot></table-wrap><p>Lastly, following
the work conducted in the azaindole
core, we
explored two small thiazole modifications that were crucial for selectivity.
Particularly, by simply adding a methyl group in position 5 (<bold>39</bold>, <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) the inhibitory activity was shifted toward Fyn (GSK-3&#946; IC<sub>50</sub> = 15.60 &#177; 3.47 &#956;M; Fyn IC<sub>50</sub> = 0.39
&#177; 0.11 &#956;M), while 2-aminothiazole replacement with a 1,3,4-thiadiazol-2-amine
nucleus powerfully switched the selective inhibition toward GSK-3&#946;
(<bold>40</bold>, GSK-3&#946; IC<sub>50</sub> = 0.020 &#177; 0.003
&#956;M).</p><p>After this hit-optimization campaign, starting from
the unbalanced
micromolar inhibitor <bold>I</bold>, we achieved two dual compounds <bold>27</bold> (GSK-3&#946; IC<sub>50</sub> = 0.28 &#177; 0.07 &#956;M;
Fyn IC<sub>50</sub> = 3.48 &#177; 0.68 &#956;M) and <bold>28</bold> (GSK-3&#946; IC<sub>50</sub> = 0.038 &#177; 0.006 &#956;M; Fyn
IC<sub>50</sub> = 0.71 &#177; 0.09 &#956;M) with increased inhibitory
potencies, albeit remaining more active toward GSK-3&#946;. Furthermore,
we identified a potent selective nanomolar GSK-3&#946; inhibitor
(<bold>40</bold>, GSK-3&#946; IC<sub>50</sub> = 0.020 &#177; 0.003
&#956;M), while compounds <bold>38</bold> (Fyn IC<sub>50</sub> =
0.55 &#177; 0.02 &#956;M) and <bold>39</bold> (Fyn IC<sub>50</sub> = 0.39 &#177; 0.11 &#956;M) were the two more potent and selective
Fyn inhibitors of the series. These results gave us preliminary information
about the structural features required to modulate the activity on
the two protein kinases. However, these activities were not yet satisfactory
in terms of Fyn inhibition for both selective inhibitors <bold>38</bold> and <bold>39</bold> as well as dual compounds <bold>27</bold> and <bold>28</bold>. Based on these results, to boost Fyn-related selective
potency, we therefore considered merging the two emerged Fyn-preferred
motifs: bromine in position 5 of 7-azaindole nucleus with methyl group
insertion in thiazole core. In this way, the two modifications were
synergic for Fyn activity, achieving the more potent and selective
Fyn inhibitor of the series (<bold>41</bold>, Fyn IC<sub>50</sub> =
0.05 &#177; 0.01 &#956;M). At the same time, to strengthen Fyn inhibitory
potency of <bold>27</bold> and <bold>28</bold> the methyl group was
inserted in their thiazole ring, affording compounds <bold>42</bold> and <bold>43</bold> (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>), respectively. In this case, Fyn IC<sub>50</sub> values
of both compounds dropped, while the GSK-3&#946; IC<sub>50</sub> value
increased by an order of magnitude with respect to the parent compounds,
highlighting GSK-3&#946;&#8242;s low tolerance for this structural
modification.</p><p>In the present study, we built upon a structure&#8211;activity
relationship (SAR) investigation based on the different modifications
made to the 3-aminothiazole-7-azaindole core regarding Fyn and GSK-3&#946;
activities, whose results are summarized in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>: (i) the 7-azaindole core was pivotal for
maintaining the inhibitory activities, whereas a 5-bromo substituent
on this core enhanced Fyn inhibition; (ii) the insertion of a methyl
group in position 5 of the central thiazole nucleus shifted the activity
toward Fyn, while the replacement of thiazole with a thiadiazole ring
switched completely the activity toward GSK-3&#946;, rendering these
modifications relevant to drive the selectivity within the two kinases;
(iii) the side tail on the amino group was the most explored for chemical
accessibility reasons and it was found that benzyl substitution was
preferred and 4-methylpyridine with halogen insertion was also well
tolerated.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Schematic representations of the results of our SAR study.</p></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="jm5c00629_0001.jpg"/></fig></sec><sec id="sec2.2"><title>Mechanism of Action of Compound <bold>43</bold>
</title><p>To
gain insights into the mechanism of GSK-3&#946; and Fyn inhibition
within this class of compounds, compound <bold>43</bold> was tested
for its ability to competitively replace ATP, as described in the <xref rid="sec4" ref-type="sec">Materials and Methods</xref> section.</p><p>Under a constant
concentration (50 nM) of the substrates ULight-GS or TK (for GSK-3&#946;
and Fyn, respectively), ATP concentrations were varied from 0.75 to
12 &#956;M or 1.5 to 24 &#956;M (for GSK-3&#946; and Fyn, respectively),
and <bold>43</bold> was tested at 0.75 and 4.5 &#956;M against GSK-3&#946;
and 0.05 and 0.3 &#956;M against Fyn. Under these experimental conditions,
we observed an increase in <italic toggle="yes">K</italic>
<sub>m</sub> constant
(Michaelis&#8211;Menten constant) but an unaltered 1/<italic toggle="yes">V</italic>
<sub>max</sub> value, when the concentration of <bold>43</bold> increased
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>), suggesting
a competition between the compound and ATP.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Lineweaver&#8211;Burk
plots of GSK-3&#946; and Fyn kinetic data
(A,B) at two concentrations of compound <bold>43</bold> (0.75 and
4.5 &#956;M, 0.05 and 0.3 &#956;M, respectively). (A) Linear regression
plot of 1/V against 1/[ATP] at given concentrations of the compound
on GSK-3&#946; and (B) on Fyn. Intersecting at the same point on
the <italic toggle="yes">y</italic>-axis indicates competitive inhibition with
respect to ATP of compound <bold>43</bold> on both targets.</p></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="jm5c00629_0002.jpg"/></fig></sec><sec id="sec2.3"><title>Computational Investigations</title><p>Based
on the experimental
outputs, we carried out molecular dynamics simulations on the complexes
obtained from traditional docking of the most interesting compounds
to rationalize at molecular level the differences of their inhibition
profile toward the two kinases. Particularly, computational investigations
revealed the ability of this series of compounds to properly accommodate
within the ATP-binding sites of the two kinases, according to the
ATP-competitive mechanism of inhibition determined by kinetic studies.
As emerged from the complete inactivity of compounds <bold>34</bold>&#8211;<bold>37</bold>, the 7-azaindole nucleus acts as an anchor
point with the hinge region of both targets through two vicinal H-bond
with the amino acid backbone of Glu83 and Met85 in Fyn (<xref rid="fig4" ref-type="fig">Figures <xref rid="fig4" ref-type="fig"/>
</xref> and <xref rid="fig5" ref-type="fig"/>) or Asp133 and Val135 in GSK-3&#946; (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig"/>
</xref> and <xref rid="fig5" ref-type="fig"/>). Moreover,
for the whole series a third essential H-bond occurs with the amino
group of aminothiazole and side chain of Asp148 in Fyn and Gln185,
Asn186, or Asp200 via the H<sub>2</sub>O-bridge in GSK-3&#946; (not
shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>).
From computational investigations it emerged that the same compound
adopts a different geometric orientation within the active site of
the two kinases: a close conformation is required for Fyn due to a
flattened binding pocket, while in GSK-3&#946; the benzyl side chain
is more free to openly rotate.</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>(A) Tridimensional binding pose of compound <bold>40</bold> within
GSK-3&#946; binding site with highlighted established interactions.
Yellow dotted lines are H-bond interactions, orange dotted line is
p-cation interaction, and green dotted line is p&#8211;p interaction.
(B) Bidimensional interaction profiles over time calculated on the
last 50 ns of molecular dynamics simulation. Green arrow is p&#8211;p
interaction, red arrow is p-cation interaction, and magenta arrows
are H-bond interactions. The number on the arrow represents how much
of a percentage of interaction is maintained over the analyzed molecular
dynamics time (last 50 ns).</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="jm5c00629_0003.jpg"/></fig><p>The driving force in kinase selectivity relies
on different thiazole
substitutions. The conversion of this core in the thiadiazole (compound <bold>40</bold>) strongly enhances GSK-3&#946;-related potency due to
an additive H-bond between its N3 and the amino group of Lys85 alongside
the benzyl group, which results to be sandwiched between a pi&#8211;pi
interaction with Phe67 and a pi-cation with the same Lys85 (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>). In parallel, the
insertion of a methyl group on thiazole causes a steric clash with
Leu132 in GSK-3&#946; (reported in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>B for compound <bold>41</bold>), forcing the molecule to be outside the binding site enough
to lose crucial interactions for activity. Conversely, in Fyn the
same substituent perfectly fits in a hydrophobic cavity while stabilizing
compound <bold>41</bold> in a suitable pose for a more efficient H-bond
between the amino group and Asp148 as well as the interaction between
bromine on the azaindole ring, acting as an acceptor, and the H-bond
donor in the Ser89 backbone (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>A).</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Tridimensional binding pose for compound <bold>41</bold> in Fyn
with highlighted surface area of the binding pocket (A) and the forced
pose potentially adopted within GSK-3&#946; with the mesh representation
of <bold>41</bold> surface pointing out the steric clash with side
chain of Leu132 (B). Yellow dotted lines are H-bond interactions,
and the magenta dotted line is the interaction between halogen and
H-bond donor.</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="jm5c00629_0004.jpg"/></fig><p>In recent years, the introduction
of different
halogen atoms in
bioactive molecules has played a pivotal role for successful drug
discovery campaigns by boosting target engagement and potency (besides
pharmacokinetic improvements) thanks to their peculiar electronic
properties.<xref rid="ref19" ref-type="bibr"/> In our case, the essential
role of halogen bonding within this class of compounds has been revealed
for the first time in the Fyn potency shift while comparing compound <bold>38</bold> (Fyn IC<sub>50</sub> = 0.55 &#177; 0.02 &#956;M) with <bold>7</bold> (Fyn IC<sub>50</sub> = 2.04 &#177; 0.53 &#956;M) due to
the new interaction between bromine atom in 5 and Ser89&#8217;s NH.
Furthermore, the same effect resulted in increased potency toward
both kinases after inserting a chlorine atom in the pyridine ring
of compound <bold>27</bold> (GSK-3&#946; IC<sub>50</sub> = 0.28 &#177;
0.07 &#956;M; Fyn IC<sub>50</sub> = 3.48 &#177; 0.68 &#956;M) vs <bold>28</bold> (GSK-3&#946; IC<sub>50</sub> = 0.038 &#177; 0.006 &#956;M;
Fyn IC<sub>50</sub> = 0.71 &#177; 0.09 &#956;M). Differently from
the phenyl, the pyridine ring already better stabilizes the side chain
by establishing several H-bonds via water bridges (Asp92 and Leu17
in Fyn, while Ile62 and Asn64 occur in GSK-3&#946; beside a stronger
pi&#8211;pi with Phe67 in the latter), but by adding the <italic toggle="yes">o</italic>-chloro an order of magnitude upgrade in potency occurred.
Particularly, in Fyn the newly inserted chlorine atom interacts with
the same Ser89 forming a halogen bond beside hydrophobic interactions
with Leu17, while in GSK-3&#946; the halogen bond engages the NH
in Asn64&#8217;s backbone in addition to hydrophobic interactions
with Ile62 and Val70 (<xref rid="fig5" ref-type="fig">Figures <xref rid="fig5" ref-type="fig"/>
</xref>A,B and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">S1A,B</ext-link>).</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Bidimensional interaction profiles over time calculated
on the
last 50 ns of molecular dynamics simulation of compounds <bold>28</bold> (A,B) and <bold>43</bold> (C,D) within Fyn (A,C) and GSK-3&#946;
(B,D). Green arrows are p&#8211;p interactions, red arrows are p-cation
interactions, magenta lines are halogen bonds, and magenta arrow are
H-bond interactions. The number on the arrow represents how much of
a percentage the interaction is maintained over the analyzed molecular
dynamics time (last 50 ns).</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="jm5c00629_0005.jpg"/></fig><p>Finally, the insertion of a methyl group in compound <bold>43</bold> allows again a perfect fixed placement within the Fyn binding
site
for optimal H-bond with Asp148 and Leu17 (<xref rid="fig5" ref-type="fig">Figures <xref rid="fig5" ref-type="fig"/>
</xref>C and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">S1C</ext-link>). Conversely,
it shows the same detrimental effect in GSK-3&#946; accommodations
by pushing our compound slightly out of the pocket and then permitting
worse halogen and pi&#8211;pi interactions, which in this case were
mitigated by the new H-bonds between Arg141 and pyridine and the secondary
amino group with Asn186 via water bridges (<xref rid="fig5" ref-type="fig">Figures <xref rid="fig5" ref-type="fig"/>
</xref>D and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">S1D</ext-link>).</p></sec><sec id="sec2.4"><title>Biological Evaluation</title><p>Once the structural features
responsible for the optimal modulation of the two kinases were identified,
we aimed to evaluate the neuromodulatory profiles of the most promising
compounds. Particularly, to possibly define the role of the two kinases
in this context, we selected the two more selective compounds, <bold>41</bold> for Fyn and <bold>40</bold> for GSK-3&#946;, along with
the two more potent dual inhibitors <bold>28</bold> and <bold>43</bold> and the completely inactive compound <bold>26</bold> as negative
internal control.</p><sec id="sec2.4.1"><title>Neurotoxicity</title><p>A preliminary cell
viability assessment
was conducted in primary rat cerebellar granule neurons (CGNs), which
are considered a reliable model for studying cellular and molecular
mechanisms of survival/apoptosis and neurodegeneration/neuroprotection.<xref rid="ref20" ref-type="bibr"/> Furthermore, primary cells provide higher quality
models, and they are more sensitive to drug treatment than immortalized
cell lines, as they form synapses and incorporate significant neuromodulatory
and trophic inputs. CGN viability was assessed after 24 h treatment
of compounds <bold>26</bold>, <bold>28</bold>, <bold>40</bold>, <bold>41</bold>, and <bold>43</bold> at clinically relevant concentrations
(i.e., 5, 10, and 25 &#956;M) using MTT assay. As reported in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>, all compounds were
not neurotoxic at tested concentrations paired with a slight increase
in the registered cell viability in comparison to the control, with
marked differences depending on the compounds. Particularly, this
effect was amplified for Fyn inhibitors (i.e., <bold>28</bold>, <bold>41</bold>, and <bold>43</bold>). As a confirmation of the facts,
a similar trend was also identified for other less active compounds
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Figure S3</ext-link>).</p><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>Neurotoxicity of the
selected compounds <bold>26</bold>, <bold>28</bold>, <bold>40</bold>, <bold>41</bold>, and <bold>43</bold> at
5, 10, and 25 &#956;M on CGNs, expressed as percentage of cell viability
compared to control. <italic toggle="yes">n</italic> = 4; ***<italic toggle="yes">p</italic> &lt; 0.001, ****<italic toggle="yes">p</italic> &lt; 0.0001 vs CTRL, One-way
ANOVA, Dunnett&#8217;s multiple comparison test.</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="jm5c00629_0006.jpg"/></fig><p>This peculiar behavior could be accountable through
the modulation
of different cellular pathways, such as the reduction of the physiological
cell mortality rate or stimulated hyperproliferation.<xref rid="ref21" ref-type="bibr"/> To figure out the putative mechanism of action within this
kinase inhibitor family, we carried out an in-depth biological investigation
dissecting one by one the different neuromodulatory pathways.</p></sec><sec id="sec2.4.2"><title>Neuroprotection</title><p>First, we evaluated the neuroprotective
properties of the selected compounds in the same cell line, once the
expression of Fyn and GSK-3&#946; in this cellular model was verified
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Figure S2</ext-link>), after a serum/potassium deprivation
experiment, which simulates physiological aging (and mortality), triggering
around 20% of cell death.<xref rid="ref22" ref-type="bibr"/> In particular,
7 days differentiated CGNs were exposed to serum-free BME medium with
low extracellular concentration of K<sup>+</sup> ions and treated
at selected doses (i.e., 5, 10, and 25 &#956;M) of compounds for
48 h. Neuronal viability was then determined with an MTT assay. After
treatment, all compounds, except the inactive compound <bold>26</bold> and the GSK-3&#946; selective compounds <bold>40</bold> (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>) or <bold>33</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Figure S4</ext-link>), not only completely rescue
neurons vitality but even induce an important cell-viability increase.
In this case, we verified the important neuroprotective profile for
Fyn-active compounds, while GSK-3&#946; selective inhibitors were
almost equipotent to inactive compounds in this respect, suggesting
that Fyn inhibition plays a crucial role in fighting neuronal aging.</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>Neuroprotection
of the selected compounds <bold>26</bold>, <bold>28</bold>, <bold>40</bold>, <bold>41</bold>, and <bold>43</bold> at
5, 10, and 25 &#956;M on CGNs, expressed as percentage of cell viability
compared to control. <italic toggle="yes">n</italic> = 4; * vs no serum no K<sup>+</sup>. One-way ANOVA, Dunnett&#8217;s multiple comparison test;
# vs CTRL; unpaired <italic toggle="yes">t</italic>-test. **<italic toggle="yes">p</italic> &lt;
0.01, ***<italic toggle="yes">p</italic> &lt; 0.001, ****<italic toggle="yes">p</italic> &lt;
0.0001 vs CTRL.</p></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="jm5c00629_0007.jpg"/></fig></sec><sec id="sec2.4.3"><title>Neural Progenitor Cell
Proliferation</title><p>Differently from
embryonic development, postnatal neurogenesis is limited to some regional
regeneration and cognitive function (e.g., in the subventricular zone
and subgranular zone of the hippocampal dentate gyrus) with gradual
loss of intensity with age. This fact paired with the development
of neurodegenerative conditions dramatically decreases the number
of existing neurons and limits the brain&#8217;s intrinsic capacity
to generate new neurons for functional replacement, with the consequent
drop in brain function.<xref rid="ref23" ref-type="bibr"/> Notably, impaired
neurogenesis in neurodegenerative diseases may result from reduced
proliferation of neural stem cells (NSCs), defective differentiation,
or a pathological shift in lineage commitment.<xref rid="ref24" ref-type="bibr"/> Therefore, the chance to pharmacologically trigger neuroregenerative
processes, by influencing both proliferation and fate determination
of neural progenitor cells (NPCs), has emerged as promising tool to
counteract neurodegeneration.<named-content content-type="bibref-group">
<xref rid="ref3" ref-type="bibr"/>,<xref rid="ref25" ref-type="bibr"/>
</named-content> Particularly, NPCs
are multipotent neural cells able to proliferate and differentiate
into neurons, astrocytes, and oligodendrocytes, and several kinases
are considered as master regulators of such neurodevelopmental processes,
among which a key role is played by GSK-3&#946;.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref26" ref-type="bibr"/>
</named-content>
</p><p>Based on that, we further investigated the neurogenic and
differentiation potential of our kinase inhibitors in cell culture
of neurospheres, which are floating pools of NPCs coming from the
subventricular zone (SVZ) of six-month-old mice. Particularly, we
first analyzed the variation, during 7 days, in number and size of
neurosphere population with and without treatment. Neurospheres physiologically
grew in number during the first 2&#8211;3 days, with a following
decrease due to physiological death of those not grown, while afterward
they increased in dimension as well as shaped branched neurites. Therefore,
single neurospheres were plated and allowed to grow spontaneously
after treatment with three different concentrations comparable to
the inhibitory potency (i.e., 0.1, 1, and 5 &#956;M) of compounds <bold>26</bold>, <bold>28</bold>, <bold>40</bold>, <bold>41</bold>, and <bold>43</bold> or DMSO as control for 7 days (<xref rid="fig8" ref-type="fig">Figures <xref rid="fig8" ref-type="fig"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">S5</ext-link>). Generally,
the tested compounds exerted mild neurogenic activity, mainly stimulating
early proliferation more than later maturation. Particularly, compounds
with higher GSK-3&#946; inhibition (i.e., <bold>28</bold> and <bold>40</bold>, <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref> and <bold>27</bold>, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Figure S5</ext-link>) demonstrated
pronounced neurogenesis, which remained notably significant up to
the fifth day at 5 &#956;M, suggesting a pivotal role in inhibiting
this kinase to achieve this activity. A premature increase in dimension
(i.e., 3&#8211;5 days) has been observed for <bold>42</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Figure S5</ext-link>), while noticeable maturation at days
6 and 7 has been verified only for compounds <bold>27</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Figure S5</ext-link>) and <bold>28</bold> (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>). For instance, in <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>, the efficiency
of treatment with compound <bold>28</bold> can be noticed in comparison
with untreated and inactive controls in terms of the boosted number
(at day 4) and dimension (at day 7) of neurospheres, while dual inhibitor <bold>43</bold> was not effective in this respect.</p><fig position="float" id="fig8" fig-type="figure" orientation="portrait"><label>8</label><caption><p>Growth analysis of neurospheres
through the evaluation of the number
of objects per image (on the left) and the total of the area of the
brightfield object in the image (on the right). Single neurospheres
were plated (5000 per well) and let spontaneously grow for 7 days.
Tested concentrations: 0.1, 1, and 5 &#956;M. Images were acquired
every 24 h. <italic toggle="yes">N</italic> = 4 &#177; SE. Two-way ANOVA, Dunnett&#8217;s
multiple comparison test. *<italic toggle="yes">p</italic> &lt; 0.05, **<italic toggle="yes">p</italic> &lt; 0.01, ***<italic toggle="yes">p</italic> &lt; 0.001 vs CTRL.</p></caption><graphic id="gr8" position="float" orientation="portrait" xlink:href="jm5c00629_0008.jpg"/></fig><fig position="float" id="fig9" fig-type="figure" orientation="portrait"><label>9</label><caption><p>Brightfield images for days 0, 4, and 7 of compounds <bold>26</bold> and <bold>28</bold> at 5 &#956;M vs control.</p></caption><graphic id="gr9" position="float" orientation="portrait" xlink:href="jm5c00629_0009.jpg"/></fig></sec><sec id="sec2.5"><title>Neural Progenitor Cell Differentiation</title><p>Lastly, we move
forward to evaluate the neuromodulatory profile of selected compounds
that involves the capability to polarize the spontaneous differentiation
of neurospheres, which potentially can maturate in neurons or macroglia,
such as astrocytes and oligodendrocytes. Modulating NPC differentiation
is especially relevant under neurodegenerative conditions as it could
offer an intriguing opportunity to achieve polyhedric therapeutic
effects. Importantly, neuronal differentiation may help to counteract
the progressive neuronal loss, while promoting oligodendrocyte phenotype
could support remyelination and neuronal function and the astrocytic
polarization may aid to foster a neuroprotective profile.<xref rid="ref27" ref-type="bibr"/> Particularly, after 7 days of treatment at 1
&#956;M, in the same experimental conditions previously reported,
cells were fixed and stained with different antibody markers such
as doublecortin (DCX) for the immature neurons, glial fibrillary acidic
protein (GFAP) for astrocytes, and oligodendrocyte transcription factor
2 (OLIG2) for oligodendrocyte precursors for immunofluorescence analysis
(<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>a). Differently
from other GSK-3&#946; inhibitors,<xref rid="ref15" ref-type="bibr"/> our
compounds did not show a marked polarization toward a neuron-specific
phenotype, except for a mild increment observed after treatment with
GSK-3&#946; selective inhibitor <bold>40</bold>, suggesting that
the simultaneous Fyn inhibition plays a detrimental role in this respect.
Instead, Fyn-active inhibitors induced a specific glial differentiation,
mainly astrocytic, while a potent and selective Fyn inhibition (e.g.,
compound <bold>41</bold>, <xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>b) was markedly deleterious for oligodendrocytes due
to the previously cited pivotal role of Fyn in oligodendrocytes maturation.<xref rid="ref28" ref-type="bibr"/> To note, this effect was mitigated in response
to dual inhibitors <bold>28</bold> and <bold>43</bold> thanks to the
beneficial role of simultaneous GSK-3&#946; inhibition in this respect.<xref rid="ref29" ref-type="bibr"/> Particularly, compounds <bold>41</bold> and <bold>43</bold> (i.e., selective and dual more potent Fyn inhibitors, respectively)
notably directed the differentiation toward the astrocytic phenotype,
promoting themselves as potential derivatives for counteracting neuroinflammatory
processes. By driving the maturation of astrocytes, compounds <bold>41</bold> and <bold>43</bold> could exert neuroprotection through
multiple mechanisms, including the secretion of neurotrophic factors,
enhancement of antioxidant defenses, regulation of water balance,
ion homeostasis, and glutamate buffering and recycling.<xref rid="ref30" ref-type="bibr"/> Furthermore, astrocytes support the integrity
of the blood&#8211;brain barrier (BBB) and aid in the refinement
of neural networks via synaptic pruning, further reinforcing their
role in preserving brain function and structure.<xref rid="ref31" ref-type="bibr"/> Finally, besides a soft neuron polarization, compound <bold>40</bold> negatively affected astrocytic differentiation and proved
to be inactive regarding oligodendrocytes, highlighting the important
role of Fyn inhibition positively in the first case and adversely
in the latter.</p><fig position="float" id="fig10" fig-type="figure" orientation="portrait"><label>10</label><caption><p>Immunostaining (a) and fluorescence intensity analysis
(b) with
differentiation markers on spontaneously differentiated neurospheres
in the presence of the selected compounds <bold>26</bold>, <bold>28</bold>, <bold>40</bold>, <bold>41</bold>, and <bold>43</bold> (1 &#956;M)
or DMSO (control). <italic toggle="yes">N</italic> = 3 &#177; SE with 3 different
fields acquired for each experiment. One-way ANOVA, Dunnett&#8217;s
multiple comparison test. *<italic toggle="yes">p</italic> &lt; 0.05, **<italic toggle="yes">p</italic> &lt; 0.01, ****<italic toggle="yes">p</italic> &lt; 0.0001 vs CTRL.</p></caption><graphic id="gr10" position="float" orientation="portrait" xlink:href="jm5c00629_0010.jpg"/></fig></sec><sec id="sec2.5.1"><title>Immunomodulation</title><p>Microglia and astrocytes
activation
represents the main defense for fighting neuroinflammation in CNS.<xref rid="ref32" ref-type="bibr"/> After identification of an inflammatory toxic
insult, a coordinated and synergic astrocyte-microglia anti-inflammatory
response occurs, upon activation, mainly through the modulation of
cytokine trafficking as well as a final coordinated deescalation until
the resting state. Furthermore, while astrocytes carry out even essential
functions to maintain CNS brain homeostasis besides as immune checkpoint
supervisors, microglia are considered the main immune effector cells
of the brain.<xref rid="ref33" ref-type="bibr"/> To gain a conclusive answer
on the potential role of these kinase inhibitors in counteracting
neuroinflammatory processes, after the verified induced astrocytic
polarization, the ability of selected compounds to modulate inflammatory
response was analyzed by favoring the immunomodulatory switch from
neurotoxic M1 phenotype of microglia to phagocytic and neuroprotective
M2 phenotype, evaluating inducible nitric oxide synthase (iNOS) and
TREM2 as M1 and M2 markers (<xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig"/>
</xref>). Particularly, M1-like is activated by inflammatory
stimuli and further fuels the inflammatory cascade by increasing proinflammatory
molecules such as iNOS. Conversely, M2-like phenotype increases neuroprotective
functions through the production of anti-inflammatory cytokines and
phagocytosis&#8217; markers.<xref rid="ref34" ref-type="bibr"/> In this
regard, Fyn and GSK-3&#946; inhibition has already been proven to
be a promising immunomodulatory strategy.<xref rid="ref35" ref-type="bibr"/> To this end, compounds <bold>26</bold>, <bold>28</bold>, <bold>40</bold>, <bold>41</bold>, and <bold>43</bold> were tested in immortalized
murine microglia N9 at 2.5 and 5 &#956;M, slightly higher concentrations
with respect to differentiation studies in neurospheres. This is due
to the low level of Fyn detected in this cell line and the different
sensitivity and responsiveness of the two proposed cellular models
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Figure S2</ext-link>). The tested compounds generally
led to a decrease of proinflammatory iNOS as a marker of M1 phenotype,
except for inactive kinase inhibitor <bold>26</bold> and GSK-3&#946;-selective <bold>40</bold>. In detail, Fyn-selective <bold>41</bold> and dual inhibitor <bold>28</bold> notably decreased the M1 marker at both tested concentrations,
while dual inhibitor <bold>43</bold> significantly reduced the M1
marker only at the highest concentration, suggesting a preferential
Fyn inhibition for pursuing anti-inflammatory activity. Parallelly,
despite some fluctuations, no significant variations of M2-marker
occurred, highlighting the potential of these compounds to modulate
glial inflammation and potentially revert proinflammatory phenotype,
preserving the phagocytic properties of microglia. Altogether, these
experimental outputs suggest the ability to modulate neuroinflammation
by interfering with the microglial M1/M2 switch, rather than totally
repressing microglia reactivity.</p><fig position="float" id="fig11" fig-type="figure" orientation="portrait"><label>11</label><caption><p>Immunomodulatory effects of the selected
compounds <bold>26</bold>, <bold>28</bold>, <bold>40</bold>, <bold>41</bold>, and <bold>43</bold> at reported concentrations in N9 cells
were evaluated through Western
blot analysis of microglial polarization markers expression (A), with
the respective densitometries of iNOS (B) and TREM2 (C) expressions.
GAPDH was used as loading control. Densitometric results are expressed
as percentage vs cells treated with LPS only and are the mean &#177;
SE of three different experiments (Student&#8217;s <italic toggle="yes">t</italic>-test). *<italic toggle="yes">p</italic> &lt; 0.05, **<italic toggle="yes">p</italic> &lt;
0.01, ***<italic toggle="yes">p</italic> &lt; 0.001 vs LPS.</p></caption><graphic id="gr11" position="float" orientation="portrait" xlink:href="jm5c00629_0011.jpg"/></fig></sec></sec><sec id="sec2.6"><title>BBB Permeability</title><p>Blood&#8211;brain barrier (BBB) crossing
represents one of the main criticisms during preclinical development
of CNS-targeting drugs. Its continuous and not fenestrated endothelium
paired with the presence of several efflux pumps (e.g., <italic toggle="yes">P</italic>-glycoprotein) strongly reduced brain permeability, therefore limiting
drug uptake at effective doses in CNS.<xref rid="ref36" ref-type="bibr"/> In this context, we preliminarily evaluated the physicochemical
properties of the two most promising compounds of the series, acting
as nanomolar dual inhibitors with immunomodulatory, neurogenic properties
for <bold>28</bold> and astrocytic polarizing effect for <bold>43</bold>, in addition to the neuroprotective activities for both compounds
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Table S1</ext-link>). If compared with the optimal
parameters for CNS drugs,<xref rid="ref37" ref-type="bibr"/> both compounds
almost perfectly fitted within this benchmarks and were in accordance
with those of CNS penetrating kinase inhibitors,<xref rid="ref38" ref-type="bibr"/> with the only exception of a not enough basic profile.
Furthermore, to corroborate their potential activity at the central
level, we experimentally assessed the BBB permeation of these two
compounds by means of a validated <italic toggle="yes">in vitro</italic> model
(<xref rid="fig12" ref-type="fig">Figure <xref rid="fig12" ref-type="fig"/>
</xref>, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Table S2</ext-link>). To this aim, the immortalized human
brain endothelial cell line (<italic toggle="yes">h</italic>CMEC/D3) was used since
it mimics the brain endothelium-restricted permeability and expresses
most of the transporters and receptors present in vivo, constituting
a valuable <italic toggle="yes">in vitro</italic> model of the human BBB crossing
system. Based on a reported protocol,<xref rid="ref39" ref-type="bibr"/> we exploited the fluorescent dye tetramethyl-rhodamine isothiocyanate
(TRITC)-dextran as a marker of passive diffusion through cell&#8211;cell
junctions, where low TRITC-dextran permeability indicates the integrity
of the endothelial monolayer. To note, low permeability to the fluorescent
dye was retained after the permeability assays of TRITC-dextran with
the tested compounds, confirming that all of them did not influence
the endothelial monolayer integrity at a concentration of 100 &#956;M
(data not shown). CNS-directed drugs such as antipyrine and donepezil
were used as positive controls, while the oligosaccharide inulin was
used as a negative control, as well as TRITC-dextran. Compound <bold>43</bold> displayed a prominent apparent permeability (Papp 10<sup>&#8211;6</sup> cm/s) of 32 &#177; 5.38, which is higher than the
two positive controls employed. However, compound <bold>28</bold>,
which differs in having only one methyl group less, showed a moderate
BBB permeability with an endothelial Papp of 12.4 &#177; 1.13, almost
to the same extent of donepezil (Papp of 15.6 &#177; 3.1).</p><fig position="float" id="fig12" fig-type="figure" orientation="portrait"><label>12</label><caption><p>Prediction
of the BBB penetration expressed as the permeability
coefficient (Papp, cm s<sup>&#8211;1</sup>) &#177; SE. Antipyrine
and donepezil were used as positive controls, while TRITC-dextran
and inulin as negative controls. *<italic toggle="yes">p</italic> &lt; 0.05, ***<italic toggle="yes">p</italic> &lt; 0.001 vs TRITC-dextran; Student&#8217;s <italic toggle="yes">t</italic>-test.</p></caption><graphic id="gr12" position="float" orientation="portrait" xlink:href="jm5c00629_0012.jpg"/></fig></sec><sec id="sec2.7"><title>Kinase Selectivity Profiling
of Compounds <bold>41</bold> and <bold>43</bold>
</title><p>Finally,
we selected compounds <bold>41</bold>, to fully evaluate its potential
because of the lack of selective
Fyn inhibitor to date, and <bold>43</bold>, due to its promising biological
activities, for a wider kinase selectivity profiling. Particularly,
both compounds were evaluated against a panel of 58 human wild-type
kinases, representative of the different families covering the kinome,
at 10 &#956;M through the Eurofins (Eurofins Cerep, Celle l&#8217;Evescault-France)
KinaseProfiler platform (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Table S3</ext-link>). Notably,
both compounds reaffirmed the inhibitory pattern toward Fyn or GSK-3&#946;
and revealed promising selectivity, with compound <bold>41</bold> confirming
a more restricted selectivity profile compared to compound <bold>43</bold>, which was properly designed to target two kinases belonging to
two different families. Interestingly, both compounds at tested concentrations,
besides Src family members Fyn and Lyn, completely inhibited LOK and
Abl kinases. Particularly, this latter is considered an important
mediator of several neurotoxic pathways (e.g., neuroinflammation,
oxidative stress or tau, A&#946; and &#945;-syn aggregates deposition)
and multitarget inhibitors of Src/Bcr-Abl family kinases have already
proven significant neuroprotective properties (i.e., dasatinib).<xref rid="ref40" ref-type="bibr"/> Albeit the role of these different kinases in
this respect has to be further investigated, Abl inhibition can confer
specific beneficial effects to the herein disclosed kinase inhibitors.
Furthermore, other main off-targets (&gt;90% inhibition) for compound <bold>41</bold> turned out to be DRAK1 and MLK1 kinases, while for compound <bold>43</bold> emerged MSK2, Rsk1, CDK9 and PKA, which mainly represented
understudied kinases or related to contradicting roles in neurodegenerative
processes. To note, some of them (e.g., MLK1, CDK9) were involved
in regulating inflammatory pathways, thus their inhibition could contribute
to the resulting anti-inflammatory profile of our inhibitors.<xref rid="ref41" ref-type="bibr"/>
</p></sec><sec id="sec2.8"><title>Chemistry</title><p>Compound <bold>I</bold> was synthesized as
previously reported.<xref rid="ref42" ref-type="bibr"/> Almost all of the
final compounds <bold>1</bold>&#8211;<bold>43</bold> were obtained
following the same two-step procedure, with variations depending on
the introduced substituents. The initial regioselective Friedel&#8211;Crafts
acylation with bromoacetyl bromide (or 2-bromopropionyl bromide for
intermediates <bold>75</bold> and <bold>76</bold>, <xref rid="sch3" ref-type="fig">Scheme <xref rid="sch3" ref-type="fig"/>
</xref>) activated position 3 of the selected nitrogen-based bicycle:
7-chloroindole for intermediate <bold>73</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Scheme S6</ext-link>), 5-bromoazaindole for <bold>74</bold> and <bold>76</bold> (<xref rid="sch3" ref-type="fig">Scheme <xref rid="sch3" ref-type="fig"/>
</xref>), 1-substituted 7-azaindole for <bold>71</bold>&#8211;<bold>72</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Scheme S5</ext-link>), and unsubstituted 7-azaindole
for all the rest. The following Hantzsch cyclization with the proper <italic toggle="yes">N</italic>-substituted thioureas allows us to obtain final aminothiazole
derivatives as hydrobromide salts. Where available, we directly exploited
commercial thioureas (such as for compounds <bold>1</bold>&#8211;<bold>15</bold>, <bold>20</bold>, <bold>22</bold>, and <bold>23</bold>, <xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>), otherwise we prepared
the required thioureas exploiting a modified three-step microwave-assisted
reported procedure (<xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>).<xref rid="ref43" ref-type="bibr"/> Reaction between benzoyl chloride,
ammonium thiocyanate, and appropriate amine led to protected thioureas
passing through benzoyl isothiocyanate intermediate. Consequent hydrolysis
under basic conditions (except for nitro derivative <bold>49</bold>, where acidic conditions were required, and for benzamide <bold>57</bold>, where needed thiourea was directly ready after ammonia
addition) resulted in thioureas <bold>45</bold>&#8211;<bold>57</bold> which underwent cyclization with <bold>44</bold> to achieve final
compounds <bold>17</bold>&#8211;<bold>33</bold> (<xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>). All of the required amines
for thioureas preparation were commercially available with the only
exception of <bold>58</bold> which was obtained from the reduction
of the corresponding nitrile (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Scheme S1</ext-link>). To obtain aniline derivatives <bold>16</bold> and <bold>25</bold>, the nitro group of benzoylated thioureas <bold>59</bold> and <bold>64</bold> was reduced in the presence of iron under acidic conditions
and, building on that, final phenyl and benzyl aminothiazole derivatives
were obtained following the previously reported procedure (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Schemes S2 and S3</ext-link>); furthermore, regarding <bold>16</bold>, Boc-protection of the amino group was needed during cyclization
step to obtain a sufficiently pure final compound after carbamate
deprotection (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Scheme S2</ext-link>). In the case of
indole <bold>34</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Scheme S4</ext-link>), the
preparation of 2-bromo acetyl chain in position 3 required a two-step
strategy: a first acylation with acetyl chloride followed by &#945;-bromination
with copper&#173;(II) bromide. For 1-functionalized derivatives <bold>35</bold> and <bold>36</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">Scheme S5</ext-link>) the initial
N-substitution with proper alkyl halides and sodium hydride, as base,
was followed by the same acylation and aminothiazole ring closure.
Finally, cyclization of benzyl thiosemicarbazide <bold>78</bold>,
obtained from hydrazine addiction to benzyl isothiocyanate, with 7-azaindole-3-carbonitrile <bold>77</bold>, prepared from 7-azaindole-3-carboxaldehyde and hydroxylamine,
furnished the 2-amino-1,3,4-thiadiazole core of compound <bold>40</bold> (<xref rid="sch4" ref-type="fig">Scheme <xref rid="sch4" ref-type="fig"/>
</xref>).</p><fig position="float" id="sch1" fig-type="scheme" orientation="portrait"><label>1</label><caption><title>Synthetic
Routes for Compounds <bold>1</bold>&#8722;<bold>15</bold>, <bold>20</bold>, <bold>22</bold> and <bold>23</bold>
<xref rid="s1fn1" ref-type="fn"/>
</title></caption><graphic id="gr13" position="float" orientation="portrait" xlink:href="jm5c00629_0013.jpg"/><p>
<fn id="s1fn1"><label>a</label><p>Reagents
and Conditions:
(i)
BrAcBr, AlCl<sub>3</sub>, DCM, Reflux, 2 h; (ii) EtOH, Reflux, 1 h.</p></fn>
</p></fig><fig position="float" id="sch2" fig-type="scheme" orientation="portrait"><label>2</label><caption><title>Synthetic Routes for Compounds <bold>17</bold>&#8722;<bold>19</bold>, <bold>21</bold>, <bold>24</bold> and <bold>26&#8722;33</bold>
<xref rid="s2fn1" ref-type="fn"/>
</title></caption><graphic id="gr14" position="float" orientation="portrait" xlink:href="jm5c00629_0014.jpg"/><p>
<fn id="s2fn1"><label>a</label><p>Reagents and Conditions:
(i)
a. NH<sub>4</sub>SCN, Acetone, MW, 15 min, 60 &#176;C; b. NHR<sub>1</sub>R<sub>2</sub>, MW, 15 min, 60 &#176;C; c. K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/EtOH, Reflux, 2 h (for <bold>49</bold> c.
HCl, Reflux, 2h; no Step c for <bold>57</bold>); (ii) <bold>44</bold>, EtOH, Reflux, 1 h.</p></fn>
</p></fig><fig position="float" id="sch3" fig-type="scheme" orientation="portrait"><label>3</label><caption><title>Synthetic Routes
for Compounds <bold>38</bold>, <bold>39</bold> and <bold>41&#8722;43</bold>
<xref rid="s3fn1" ref-type="fn"/>
</title></caption><graphic id="gr15" position="float" orientation="portrait" xlink:href="jm5c00629_0015.jpg"/><p>
<fn id="s3fn1"><label>a</label><p>Reagents and Conditions:
(i)
BrAcBr or 2-BrPrBr, AlCl<sub>3</sub>, DCM, Reflux, 2 h; (ii) R<sub>3</sub>-thiourea, EtOH, Reflux, 1 h.</p></fn>
</p></fig><fig position="float" id="sch4" fig-type="scheme" orientation="portrait"><label>4</label><caption><title>Synthetic
Route for Compound <bold>40</bold>
<xref rid="s4fn1" ref-type="fn"/>
</title></caption><graphic id="gr16" position="float" orientation="portrait" xlink:href="jm5c00629_0016.jpg"/><p>
<fn id="s4fn1"><label>a</label><p>Reagents and Conditions:
(i)
NH<sub>2</sub>OH, HCOOH, HCOONH<sub>4</sub>, Reflux, 2 h; (ii) (NH<sub>2</sub>)<sub>2</sub>, DCM, rt, 2 h; (iii) TFA, Reflux, 2 h.</p></fn>
</p></fig></sec></sec><sec id="sec3"><title>Conclusions</title><p>The chance to develop
late-stage treatments
which could promote
the recovery of neural trophism by favoring the switch from neurodegenerative
to neuroregenerative processes paired with neuroprotective activities
emerged as a promising paradigm for CNS-directed drug discovery programs.
Pursuing this approach, we identified protein kinases Fyn and GSK-3&#946;
as valid targets in this respect due to their multifaceted involvement
in both activation and fostering of neurotoxic pathways besides the
modulation of neurogenic/neurodevelopmental processes. Thus, in search
of Fyn/GSK-3&#946; inhibitors, we have herein sought to develop new
dual kinase inhibitors starting from the pharmacophore of the 7-azaindole-3-aminothiazole,
endowed with a mild and unbalanced Fyn/GSK-3&#946; kinase inhibitor
profile. After deepened SAR studies, we achieved two selective inhibitors,
one Fyn-referred and one for GSK-3&#946; (<bold>41</bold> and <bold>40</bold>, respectively), and two dual nanomolar inhibitors (compounds <bold>28</bold> and <bold>43</bold>) that, together with an inactive compound
of the series, enabled us to investigate the role of the two kinases
regarding neuromodulatory and neuroprotective properties. An initial
evaluation in a primary neuron cell culture highlighted no toxicity
issues paired with an unusual increase in the registered cell viability,
which was amplified in the more potent Fyn inhibitors, stimulating
the following biological investigations to define the underlying mechanism.
First, the ability to mitigate the physiological senescence and mortality
rate was noticed only for Fyn-selective (compound <bold>41</bold>)
and dual inhibitors (compounds <bold>28</bold> and <bold>43</bold>), reaffirming an important role for Fyn inhibition in tackling neuronal
aging. Second, tested inhibitors proved to trigger both proliferation
and neuromodulation of neural progenitor cells, with slightly different
behavior depending on their kinase inhibition profile: marked neurogenesis
after treatment with GSK-3&#946;, more potent inhibitors <bold>40</bold> and <bold>28</bold> and pronounced glial differentiation with Fyn,
more potent inhibitors <bold>41</bold> and <bold>43</bold>. Finally,
the selected inhibitors generally tuned inflammatory response by reducing
microglial pro-inflammatory activation without repressing its anti-inflammatory
reactivity, emerging with remarkable immunomodulatory activities for
compounds <bold>28</bold> and <bold>41</bold>.</p><p>Although a promising
selectivity emerged for <bold>41</bold> and <bold>43</bold>, further
improvements in this regard are needed to fully
depict kinases involvement. Ultimately, the resulting dual inhibitors <bold>28</bold> and <bold>43</bold>, albeit still not perfectly balanced,
represent valuable pharmacological tools due to their polyhedral neuroprotective
and neuromodulatory profiles combined with proven <italic toggle="yes">in vitro</italic> BBB-permeability. Furthermore, extensive evaluation under pathological
conditions becomes necessary and will be carried out to further verify
their therapeutic properties and plausibly lay the ground for the
future development of potential dual neuroprotective-neuroregenerative
agents.</p></sec><sec id="sec4"><title>Material and Methods</title><sec id="sec4.1"><title>Chemistry</title><p>Chemical
reagents were purchased from Merck,
TCI, and Fluorochem. Nuclear magnetic resonance spectra (NMR) were
recorded at 400 MHz for <sup>1</sup>H and 100 MHz for <sup>13</sup>C on a Varian VXR 400 spectrometer or Bruker Avance III 400 system
equipped with a BBI probe and Z-gradients in CDCl<sub>3</sub>, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, or CD<sub>3</sub>OD as solvents. Chemical
shifts (d) are given in ppm from tetramethylsilane (TMS) with the
solvent resonance as the internal standard (CDCl<sub>3</sub>: &#948;
7.26, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>: &#948; 2.50, CD<sub>3</sub>OD: &#948; 3.31 for <sup>1</sup>H NMR and CDCl<sub>3</sub>: &#948;
77.16, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>: &#948; 39.52, CD<sub>3</sub>OD: &#948; 49.00 for <sup>13</sup>C NMR). For <sup>1</sup>H NMR, data are reported as follows: chemical shift, multiplicity
(s = singlet, d = doublet, dd = double of doublets, t = triplet, q
= quartet, m = multiplet, p = pentet, dt = doublet of triplets, td
= triplet of doublets, tt = triplet of triplets, qd = quartet of doublets,
br s = broad singlet), coupling constants (Hz), and integration. Microwave-assisted
synthesis was performed by using CEM Discover Standard Precision (SP)
apparatus (2.45 GHz, maximum power of 300 W). Melting points were
measured in glass capillary tubes on a Stuart SMP-10 apparatus and
are uncorrected. Chromatographic separations were performed on silica
gel columns through flash or gravity column (Kieselgel 40, 0.040&#8211;0.063
mm; Merck) chromatography. Reactions were followed by thin-layer chromatography
(TLC) on Merck (0.25 mm) glass-packed precoated silica gel plates
(60 F254) that were visualized in an iodine chamber or with a UV lamp,
KMnO<sub>4</sub>, or bromocresol green. All names were attributed
by Chem BioDraw Ultra 22.2.0. Final compounds mass spectra were recorded
on a Waters ACQUITY ARC UHPLC/MS system. All final compounds were
pure &gt;95% as determined via UHPLC/MS analyses run on a Waters ACQUITY
ARC UHPLC/MS system, consisting of a QDa mass spectrometer equipped
with an electrospray ionization interface and a 2489 UV/vis detector.
The detected wavelengths (&#955;) were 254 and 365 nm. The analyses
were performed on an XBridge BEH C18 column (10 mm &#215; 2.1 mm i.d.,
particle size 2.5 &#956;m) with an XBridge BEH C18 VanGuard Cartridge
precolumn (5 mm &#215; 2.1 mm i.d., particle size 1.8 &#956;m). The
mobile phases were H<sub>2</sub>O (0.1% formic acid) (A) and MeCN
(0.1% formic acid) (B). Electrospray ionization in positive and negative
modes was applied in the mass scan range of 50&#8211;1200 Da. Method
and gradients used were the following: hydrophilic gradient: 0&#8211;0.5
min, 5% B; 0.5&#8211;1.5 min, 25% B; 1.5&#8211;2 min, 25% B; 2&#8211;3.5
min, 70% B; 3.5&#8211;3.9 min, 70% B; 3.90&#8211;4 min, 5% B; 4&#8211;5.73
min, 5% B; generic gradient: 0&#8211;0.78 min, 20% B; 0.78&#8211;2.87
min, 20&#8211;95% B; 2.87&#8211;3.54 min, 95% B; 3.54&#8211;3.65
min, 95&#8211;20% B; 3.65&#8211;5.73, 20% B. Flow rate: 0.8 mL/min.
Generic gradient was used for all compounds apart from compounds <bold>10</bold>, <bold>16</bold>, <bold>25</bold>, <bold>27</bold>&#8211;<bold>30</bold>, <bold>40</bold>, and <bold>42</bold> that required hydrophilic
gradient.</p><sec id="sec4.1.1"><title>General Procedure A: Friedel-Craft Acylation</title><p>To a solution
of 7-azaindole, or analogues, (1 equiv) in anhydrous DCM (25 mL),
AlCl<sub>3</sub> (3 equiv) was slowly added and the reaction mixture
was left stirring for 15 min. Then, the respective acyl bromide (1.1
equiv) was added dropwise and the reaction was monitored by TLC. After
1 h, the reaction was allowed to cool down to room temperature and
quenched with water (25 mL). The obtained mixture was extracted, the
organic layer dried over sodium sulfate, and the resulting crude purified
by column chromatography to obtain the pure product.</p></sec><sec id="sec4.1.2"><title>General Procedure
B: Thiourea Preparation</title><p>A mixture
of benzoyl chloride (1 equiv) and ammonium thiocyanate (1.2 equiv)
was stirred in acetone (1&#8211;3 mL) under microwave irradiation
(60 &#176;C, 250 psi, 80 W) for 15 min. After this time, the opportune
substituted benzylamine or aniline (1 equiv) was added and the mixture
was irradiated for additional 15 min under the same condition. Then,
the reaction mixture was filtered, the precipitate was washed with
acetone, and the filtrate concentrated under vacuo. The resulting
crude was dissolved in the minimal amount of EtOH (1&#8211;2 mL)
and a solution of K<sub>2</sub>CO<sub>3</sub> 2 M (2 equiv) was added
dropwise at room temperature. To obtain intermediate <bold>49</bold>, the resulting crude product was directly suspended in HCl 37% (7
mL). The reaction was stirred at reflux for 2h and it was monitored
by TLC. After this period, the reaction mixture was cooled down to
room temperature and water (10&#8211;20 mL) was added dropwise (to
obtain intermediate <bold>49</bold> the mixture was previously basified
with 30% NH<sub>4</sub>OH<sub>(aq)</sub> until pH 8). After extraction
with DCM (4 &#215; 20 mL), the organic phases were reunited, dried
with sodium sulfate, filtered, and concentrated under vacuo. The obtained
crude product was purified with column chromatography to give the
pure products.</p></sec><sec id="sec4.1.3"><title>General Procedure C: Hantzsch Cyclization</title><p>A mixture
of bromoacetyl-intermediate (1 equiv) and the opportune thiourea (1
equiv) in EtOH or acetonitrile (2&#8211;4 mL) was stirred at reflux
for 1 h and the reaction was monitored by TLC. Then, the reaction
mixture was cooled to room temperature and then put in an ice and
salt bath for 20 min. A colored solid separated out that was filtered
and washed using cold EtOH and then dried under vacuum to obtain the
pure product.</p><sec id="sec4.1.3.1"><title>2-Bromo-1-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;ethan-1-one (<bold>44</bold>)</title><p>Compound <bold>44</bold> was obtained following general procedure A using 7-azaindole
(1.0 g, 8.46 mmol) and bromoacetyl bromide. Compound was eluted with
DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.6/0.4/0.05) which
afforded <bold>44</bold> as an off-white solid (1.35 g, 67%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.67 (br s, 1H), 8.63 (s, 1H), 8.45 (d, <italic toggle="yes">J</italic> = 8 Hz,
1H), 8.35 (d, <italic toggle="yes">J</italic> = 8 Hz, 1H), 7.29&#8211;7.27 (m,
1H), 4.69 (s, 2H). <sup>13</sup>C NMR (DMSO- <italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 187.08, 144.70, 136.15, 134.38, 130.38,
118.87, 118.54, 112.72, 33.67.</p></sec><sec id="sec4.1.3.2"><title>2-Bromo-1-(5-bromo-1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;ethan-1-one
(<bold>74</bold>)</title><p>Compound <bold>74</bold> was obtained following
general procedure A using 5-bromo-7-azaindole
(500 mg, 2.54 mmol) and bromoacetyl bromide. Compound was eluted with
DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.5/0.5/0.05) which
afforded <bold>64</bold> as a light-brown solid (680 mg, 84%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.90 (br s, 1H), 8.68 (s, 1H), 8.54 (s, 1H), 8.42 (s, 1H), 4.70 (s,
2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100
MHz): &#948; 187.03, 147.89, 145.19, 137.34, 131.68, 119.87, 114.23,
112.16, 33.56.</p></sec><sec id="sec4.1.3.3"><title>2-Bromo-1-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;propan-1-one (<bold>75</bold>)</title><p>Compound <bold>65</bold> was obtained following general procedure A using 7-azaindole
(250 mg, 2.12 mmol) and 2-bromopropionyl bromide. Compound was eluted
with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.8/0.2/0.05) which
afforded <bold>65</bold> as a yellow solid (450 mg, 79%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.68
(br s, 1H), 8.67 (s, 1H), 8.47 (d, <italic toggle="yes">J</italic> = 7 Hz, 1H),
8.35 (d, <italic toggle="yes">J</italic> = 7 Hz, 1H), 7.30&#8211;7.27 (m, 1H),
5.67 (q, <italic toggle="yes">J</italic> = 6.8 Hz, 1H), 1.78 (d, <italic toggle="yes">J</italic> = 6.8 Hz, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 188.82, 149.03, 144.46, 135.05, 129.53, 118.25,
117.95, 111.41, 44.48, 20.42.</p></sec><sec id="sec4.1.3.4"><title>2-Bromo-1-(5-bromo-1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;propan-1-one
(<bold>76</bold>)</title><p>Compound <bold>66</bold> was obtained following
general procedure A using 5-bromo-7-azaindole
(300 mg, 1.52 mmol) and 2-bromopropionyl bromide. Compound was eluted
with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.8/0.2/0.05) which
afforded <bold>66</bold> as a light-brown solid (250 mg, 50%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.89 (br s, 1H), 8.70 (d, <italic toggle="yes">J</italic> = 4 Hz, 1H), 8.55 (d, <italic toggle="yes">J</italic> = 4 Hz, 1H), 8.41&#8211;8.40 (m, 1H), 5.63 (q, <italic toggle="yes">J</italic> = 8 Hz, 1H), 1.74 (d, <italic toggle="yes">J</italic> = 8 Hz, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948;
189.42, 148.01, 145.22, 136.99, 131.81, 120.22, 114.21, 111.52, 44.88,
20.84.</p></sec><sec id="sec4.1.3.5"><title>1-(2-Methoxybenzyl)&#173;thiourea (<bold>45</bold>)</title><p>Compound <bold>45</bold> was obtained following general
procedure B using (2-methoxyphenyl)&#173;methanamine
(0.46 mL, 3.56 mmol). Compound was eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.5/0.5/0.05) which afforded <bold>45</bold> as a pale-yellow solid (200 mg, 29%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 7.76 (br s, 1H), 7.27&#8211;7.22
(m, 1H), 7.19 (d, <italic toggle="yes">J</italic> = 7 Hz, 1H), 7.05 (br s, 2H),
6.98 (d, <italic toggle="yes">J</italic> = 7 Hz, 1H), 6.91 (t, <italic toggle="yes">J</italic> = 7 Hz, 1H), 4.55 (s, 2H), 3.80 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 183.87, 157.18, 133.11,
128.70, 126.99, 120.53, 110.92, 55.75, 43.27.</p></sec><sec id="sec4.1.3.6"><title>1-(2-Chlorobenzyl)&#173;thiourea
(<bold>46</bold>)</title><p>Compound <bold>46</bold> was obtained following
general procedure B using (2-chlorophenyl)&#173;methanamine
(0.17 mL, 1.42 mmol). Compound was eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.7/0.3/0.05) which afforded <bold>46</bold> as a pale-yellow solid (260 mg, 91%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 7.96 (br s, 1H), 7.42 (d, <italic toggle="yes">J</italic> = 8 Hz, 1H), 7.32&#8211;7.26 (m, 3H), 7.18 (br s, 2H),
4.68 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 184.23, 136.88. 132.38, 129.52, 129.41, 129.05,
127.52, 45.61.</p></sec><sec id="sec4.1.3.7"><title>1-(3-Chlorobenzyl)&#173;thiourea (<bold>47</bold>)</title><p>Compound <bold>47</bold> was obtained following general
procedure B using (3-chlorophenyl)&#173;methanamine
(0.46 mL, 3.56 mmol). Compound was eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.6/0.4/0.05) which afforded <bold>47</bold> as a pale-yellow solid (470 mg, 66%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 8.04 (br s, 1H), 7.38&#8211;7.29
(m, 3H), 7.24 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H) 7.16 (br s, 2H),
4.65 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 184.09, 142.59, 133.34, 130.57, 127.37, 127.17,
126.34, 47.09.</p></sec><sec id="sec4.1.3.8"><title>1-(4-Fluorobenzyl)&#173;thiourea (<bold>48</bold>)</title><p>Compound <bold>48</bold> was obtained following general
procedure B using (4-fluorophenyl)&#173;methanamine
(0.12 mL, 1.01 mmol). Compound was eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.5/0.5/0.05) which afforded <bold>48</bold> as a pale-yellow solid (130 mg, 70%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 8.04 (br s, 1H), 7.34&#8211;7.31
(m, 2H), 7.17&#8211;7.12 (m, 4H), 4.60 (s, 2H). <sup>13</sup>C NMR
(DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 183.90, 162.85,
129.71, 115.51 (2C) 115.29 (2C), 47.05.</p></sec><sec id="sec4.1.3.9"><title>1-(4-Nitrobenzyl)&#173;thiourea
(<bold>49</bold>)</title><p>Compound <bold>49</bold> was obtained following
general procedure B using (4-nitrobenzyl)&#173;methanamine
(671 mg, 3.56 mmol). Compound was eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.5/0.5/0.05) which afforded <bold>49</bold> as a pale-yellow solid (150 mg, 20%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 8.17 (d, <italic toggle="yes">J</italic> = 8 Hz, 2H), 8.12 (br s, 1H), 7.49 (d, <italic toggle="yes">J</italic> = 8 Hz,
2H), 7.22 (br s, 2H), 4.75 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 182.50, 146.82, 128.60,
128.48 (2C), 127.85, 123.84 (2C), 47.06.</p></sec><sec id="sec4.1.3.10"><title>1-(4-(Dimethylamino)&#173;benzyl)&#173;thiourea
(<bold>50</bold>)</title><p>Compound <bold>50</bold> was obtained following
general procedure
B using 4-(aminomethyl)-<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethylaniline
(0.34 mL, 2.33 mmol). Compound was eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.8/0.2/0.05) which afforded <bold>50</bold> as a pale-yellow solid (283 mg, 88%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 7.74 (br s, 1H), 7.09 (d, <italic toggle="yes">J</italic> = 8 Hz, 2H), 6.91 (br s, 2H), 6.65 (d, <italic toggle="yes">J</italic> = 8 Hz, 2H), 4.42 (s, 2H), 2.82 (s, 6H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 183.43, 150.17, 128.93
(2C), 126.81, 112.78 (2C), 47.71, 40.71 (2C).</p></sec><sec id="sec4.1.3.11"><title>1-(Pyridin-4-ylmethyl)&#173;thiourea
(<bold>51</bold>)</title><p>Compound <bold>51</bold> was obtained following
general procedure B using 4-pyridylmethaneamine
(0.46 mL, 3.56 mmol). Compound was eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (8.7/1.3/0.1) which afforded <bold>51</bold> as a pale-yellow solid (260 mg, 45%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 8.49 (d, <italic toggle="yes">J</italic> = 5.6 Hz, 2H), 7.24 (d, <italic toggle="yes">J</italic> = 5.6 Hz, 2H), 4.67 (s,
2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100
MHz): &#948; 182.45, 128.83 (2C), 127.58, 127.50 (2C), 56.31.</p></sec><sec id="sec4.1.3.12"><title>1-((2-Chloropyridin-4-yl)&#173;methyl)&#173;thiourea
(<bold>52</bold>)</title><p>Compound <bold>52</bold> was obtained following
general procedure
B using compound <bold>58</bold> (310 mg, 2.17 mmol). Compound was
eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.5/0.5/0.05)
which afforded <bold>52</bold> as a yellowish solid (298 mg, 68%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
8.31 (d, <italic toggle="yes">J</italic> = 4.0 Hz, 1H), 8.07 (br s, 1H), 7.29&#8211;7.23
(m, 4H) 4.65 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 184.45, 153.67, 150.69, 150.13, 122.51,
121.93, 46.31.</p></sec><sec id="sec4.1.3.13"><title>1-(Pyrimidin-2-ylmethyl)&#173;thiourea (<bold>53</bold>)</title><p>Compound <bold>53</bold> was obtained following general
procedure
B using pyrimidin-2-ylmethanamine (388 mg, 3.56 mmol). Compound was
eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.5/0.5/0.05)
which afforded <bold>53</bold> as a pale-yellow solid (280 mg, 48%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
8.75 (d, <italic toggle="yes">J</italic> = 7.0 Hz, 2H), 8.01 (br s, 1H), 7.38 (t, <italic toggle="yes">J</italic> = 7.0 Hz, 1H), 7.26 (br s, 2H), 4.79 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 183.91,
166.77, 157.74 (2C), 120.29, 50.32.</p></sec><sec id="sec4.1.3.14"><title>1-(Pyrazin-2-ylmethyl)&#173;thiourea
(<bold>54</bold>)</title><p>Compound <bold>54</bold> was obtained following
general procedure B using pyrazin-2-ylmethanamine
(388 mg, 3.56 mmol). Compound was eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.5/0.5/0.05) which afforded <bold>54</bold> as a pale-yellow solid (370 mg, 62%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 8.56&#8211;8.51 (m, 3H),
8.13 (br s, 1H), 7.27 (br s, 2H), 4.75 (s, 2H). <sup>13</sup>C NMR
(DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 184.25, 154.48,
144.26, 143.83, 143.49, 47.52.</p></sec><sec id="sec4.1.3.15"><title>1-Benzyl-1-methylthiourea
(<bold>55</bold>)</title><p>Compound <bold>55</bold> was obtained following
general procedure B using <italic toggle="yes">N</italic>-methylbenzylamine (0.46
mL, 3.56 mmol). Compound was eluted
with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.8/0.2/0.05) which
afforded <bold>55</bold> as a pale-yellow solid (180 mg, 28%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
7.39 (br s, 2H) 7.36&#8211;7.32 (m, 2H), 7.27&#8211;7.24 (m, 3H),
4.99 (s, 2H), 3.33 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 184.45, 150.74, 150.00, 149.85, 122.57,
122.46, 121.69, 46.61, 42.22.</p></sec><sec id="sec4.1.3.16"><title>1-Phenethylthiourea (<bold>56</bold>)</title><p>Compound <bold>56</bold> was obtained following
general procedure B using 2-phenylethan-1-amine
(0.46 mL, 3.56 mmol). Compound was eluted with DCM/MeOH/30% NH<sub>4</sub>OH<sub>(aq)</sub> (9.7/0.3/0.05) which afforded <bold>56</bold> as a white solid (390 mg, 61%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 7.53 (br s, 1H), 7.30&#8211;7.26
(m, 2H), 7.22&#8211;7.17 (m, 3H), 6.94 (br s, 2H), 3.57&#8211;3.56
(m, 2H), 2.76 (t, <italic toggle="yes">J</italic> = 6.0 Hz, 2H). <sup>13</sup>C
NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 183.59,
139.78, 129.08 (2C), 128.75 (2C), 126.53, 45.70, 35.31.</p></sec><sec id="sec4.1.3.17"><title>
<italic toggle="yes">N</italic>-Carbamothioylbenzamide (<bold>57</bold>)</title><p>A mixture
of benzoyl chloride (0.41 mL, 3.56 mmol) and ammonium
thiocyanate (298 mg, 3.92 mmol) was suspended in acetone (2 mL) and
stirred under microwave irradiation (60 &#176;C, 80 W, 250 psi) for
15 min. The mixture was then filtered, the precipitate was washed
with acetone, and the filtrate concentrated under vacuo. The resulting
crude product was further suspended in an aqueous ammonia 30% solution
(1.78 mL) with acetone (2 mL) and stirred at room temperature for
30 min. After completion, the reaction mixture was then placed at
0 &#176;C and cold ethanol was added dropwise. The precipitate formed
was filtered, washed with cold EtOH, and dried under vacuum to obtain
the pure product as an off-white solid (210 mg, 33%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 11.20
(br s, 1H), 9.82 (br s, 1H), 9.53 (br s, 1H), 7.90&#8211;7.88 (m,
2H), 7.62&#8211;7.58 (m, 1H), 7.47 (t, <italic toggle="yes">J</italic> = 8.0 Hz,
2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100
MHz): &#948; 182.49, 168.20, 133.39, 132.68, 128.99, 128.81.</p></sec><sec id="sec4.1.3.18"><title>1<italic toggle="yes">H</italic>-Pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridine-3-carbonitrile
(<bold>77</bold>)</title><p>To a solution of 7-azaindole-3-carbaldehyde
(250 mg, 1.71 mmol) in formic acid (1.7 mL), hydroxylamine hydrochloride
(170 mg, 2.57 mmol), and ammonium formate (220 mg, 3.42 mmol) were
added, and the reaction was left stirring at reflux for 2 h, monitored
by TLC. After completion, the reaction was cooled down to room temperature,
and water (5 mL) was added dropwise. The obtained precipitate was
filtered, washed with water, and dried under vacuum to obtain the
pure product as a white powder (100 mg, 41%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.83 (br s, 1H), 8.44
(s 1H), 8.42 (d, <italic toggle="yes">J</italic> = 4.8 Hz, 1H), 8.12 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H), 7.31&#8211;7.28 (m, 1H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 147.38,
145.02, 135.51, 127.31, 118.87, 117.86, 115.56, 83.24.</p></sec><sec id="sec4.1.3.19"><title>
<italic toggle="yes">N</italic>-Benzylhydrazinecarbothioamide (<bold>78</bold>)</title><p>Benzylisothiocyanate (250 mg, 1.68 mmol) and hydrazine
hydrate (250 mg, 5.03 mmol) were suspended in DCM (1.5 mL), and the
reaction was stirred for 2 h at room temperature and monitored by
TLC. The resulting precipitate was filtered, washed with DCM, and
dried in vacuo to obtain the pure compound as a yellow solid (200
mg, 65%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>,
400 MHz): &#948; 8.70 (br s,1H), 8.25 (br s, 1H), 7.29&#8211;7.24
(m, 4H), 7.20&#8211;7.17 (m, 1H), 4.68 (d, <italic toggle="yes">J</italic> = 4.0
Hz, 1H), 4.47 (br s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 182.01, 140.23, 128.51 (2C), 127.75
(2C), 127.07, 46.57.</p></sec><sec id="sec4.1.3.20"><title>
<italic toggle="yes">N</italic>-Methyl-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide
(<bold>1</bold>)</title><p>Compound <bold>1</bold> was obtained following
general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-methyl
thiourea (57 mg, 0.63 mmol), affording it as a yellowish solid (145
mg, 74%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>,
400 MHz): &#948; 12.29 (br s, 1H), 9.31 (br s, 1H), 8.38&#8211;8.36
(m, 2H), 8.11 (s, 1H), 7.28 (dd, <sup>1</sup>
<italic toggle="yes">J</italic> =
4.8 Hz, <sup>2</sup>
<italic toggle="yes">J</italic> = 5.2 Hz, 1H), 7.10 (s, 1H),
3.07 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 169.48, 147.28, 142.73, 136.01, 129.03, 126.26,
117.35, 116.57, 105.04, 98.99, 31.99. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 231.11 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.21"><title>
<italic toggle="yes">N</italic>-Butyl-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide (<bold>2</bold>)</title><p>Compound <bold>2</bold> was obtained following general
procedure C using <bold>44</bold> (100 mg, 0.42 mmol) and 1-butylthiourea
(55 mg, 0.42 mmol), affording it as a yellowish solid (44 mg, 29%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.26 (br s, 1H), 9.29 (br s, 1H), 8.36 (d, <italic toggle="yes">J</italic> = 4.8
Hz, 2H), 8.06 (d, <italic toggle="yes">J</italic> = 6.0 Hz, 1H), 7.29&#8211;7.26
(m, 1H), 7.06 (d, <italic toggle="yes">J</italic> = 4.0 Hz, 1H), 3.45&#8211;3.44
(m, 2H), 1.65&#8211;1.59 (m, 2H), 1.43&#8211;1.37 (m, 2H), 0.93
(t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.40, 147.12, 142.53,
128.91, 126.04, 117.28, 116.38, 116.06, 105.18, 98.75, 45.38, 29.96,
19.33, 13.46. MS [ESI+]: 273.12 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.22"><title>
<italic toggle="yes">N</italic>-(2-Methoxyethyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide (<bold>3</bold>)</title><p>Compound <bold>3</bold> was obtained following general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-(4-methoxyethyl)
thiourea (85 mg, 0.63 mmol), affording it as an orange solid (121
mg, 54%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>,
400 MHz): &#948; 12.31 (br s, 1H), 9.30 (br s, 1H), 8.40 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 2H), 8.38 (d, <italic toggle="yes">J</italic> = 4.0 Hz, 2H)
8.08 (s, 1H), 7.31&#8211;7.27 (m, 1H), 7.06 (s, 1H), 3.65 (d, <italic toggle="yes">J</italic> = 4.2 Hz, 2H), 3.58 (t, <italic toggle="yes">J</italic> = 4.2 Hz, 2H),
3.32 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.76, 146.85, 142.28, 129.50, 126.25, 126.21,
117.67, 116.50, 105.52, 99.20, 69.80, 58.17, 45.40. MS [ESI+]: 275.12
[M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.23"><title>
<italic toggle="yes">N</italic>-Allyl-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide
(<bold>4</bold>)</title><p>Compound <bold>4</bold> was obtained following
general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-allyl
thiourea (73 mg, 0.63 mmol), affording it as a yellow solid (149 mg,
70%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400
MHz): &#948; 12.35 (br s, 1H), 9.31 (br s, 1H), 8.43 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.37 (d, <italic toggle="yes">J</italic> = 4.6 Hz, 1H),
8.08 (s, 1H), 7.30 (dd, <sup>1</sup>
<italic toggle="yes">J</italic> = 4.6 Hz, <sup>2</sup>
<italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.09 (s, 1H), 5.98&#8211;5.88
(m, 1H), 5.34 (d, <italic toggle="yes">J</italic> = 17.2 Hz, 1H), 5.24 (d, <italic toggle="yes">J</italic> = 10.8 Hz, 1H), 4.10 (d, <italic toggle="yes">J</italic> = 5.2 Hz,
2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100
MHz): &#948; 168.83, 146.55, 142.02, 136.99, 133.05, 130.12, 126.42,
118.06, 117.50, 116.65, 106.09, 99.56, 47.80. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 257.15 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.24"><title>
<italic toggle="yes">N</italic>-Cyclohexyl-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide (<bold>5</bold>)</title><p>Compound <bold>5</bold> was obtained following general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-cyclohexyl
thiourea (100 mg, 0.63 mmol), affording it as a pale-yellow solid
(138 mg, 58%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.29 (br s, 1H), 9.44 (br s, 1H), 8.35&#8211;8.33
(m, 2H), 8.08 (s, 1H), 7.29&#8211;7.26 (m, 1H), 7.04 (s, 1H), 3.78&#8211;3.76
(m, 1H), 1.99&#8211;1.95 (m, 2H), 1.76&#8211;1.69 (m, 2H), 1.60&#8211;1.57
(m, 1H), 1.38&#8211;133 (m, 4H), 1.24&#8211;1.18 (m, 1H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 167.75,
147.57, 143.04, 135.90, 129.46, 126.80, 117.93, 116.95, 105.36, 99.57,
55.08, 32.12, 25.25, 24.49. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 299.23 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.25"><title>
<italic toggle="yes">N</italic>-Phenyl-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
(<bold>6</bold>)</title><p>Compound <bold>6</bold> was obtained following
general procedure
C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-phenyl thiourea
(96 mg, 0.63 mmol), affording it as a yellow solid (73 mg, 31%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.49 (br s, 1H), 10.32 (br s, 1H), 8.82 (d, <italic toggle="yes">J</italic> =
7.6 Hz, 1H), 8.44 (d, <italic toggle="yes">J</italic> = 5.2 Hz, 1H), 8.09 (s, 1H),
7.73 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 2H), 7.44 (dd, <italic toggle="yes">J</italic>
<sup>1</sup> = 5.2 Hz, <italic toggle="yes">J</italic>
<sup>2</sup> = 7.8 Hz, 1H),
7.36 (t, <italic toggle="yes">J</italic> = 8.0 Hz, 2H), 7.22 (s, 1H), 6.98 (t, <italic toggle="yes">J</italic> = 7.2 Hz, 1H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 163.14, 144,43, 141.23, 139.02, 132.59,
129.18, 129.09 (2C), 125.88, 121.93, 121.34, 119.65, 117.35, 117.05
(2C), 116.11, 111.33, 100.58. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 293.13 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.26"><title>
<italic toggle="yes">N</italic>-Benzyl-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>7</bold>)</title><p>Compound <bold>7</bold> was
obtained following general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-benzyl
thiourea (105 mg, 0.63 mmol), affording it as a pale-yellow solid
(124 mg, 51%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.37 (br s, 1H), 9.48 (br s, 1H), 8.44 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.38 (d, <italic toggle="yes">J</italic> = 4.8 Hz, 1H),
8.11 (s, 1H), 7.45&#8211;7.37 (m, 4H), 7.33&#8211;7.28 (m, 2H),
7.07 (s, 1H), 4.68 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.67, 146.07, 141.41, 137.07, 130.39,
128.61 (2C), 128.48, 127.75 (2C), 127.63, 127.54, 126.21, 118.16,
116.40, 99.31, 48.78. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 307.13 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.27"><title>
<italic toggle="yes">N</italic>-(Naphthalen-1-yl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>8</bold>)</title><p>Compound <bold>8</bold> was
obtained following general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-naphthyl
thiourea (127 mg, 0.63 mmol), affording it as a pinkish solid (150
mg, 56%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>,
400 MHz): &#948; 12.60 (br s, 1H), 10.41 (br s, 1H), 8.81 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 8.47 (d, <italic toggle="yes">J</italic> = 5.6 Hz, 1H),
8.32&#8211;8.30 (m, 1H), 8.26 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H),
8.106 (s, 1H), 7.98&#8211;7.96 (m, 1H), 7.73 (d, <italic toggle="yes">J</italic> = 8 Hz, 1H), 7.60&#8211;7.57 (m, 3H), 7.46&#8211;7.43 (m, 1H),
7.26 (s, 1H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 166.42, 143.25, 143.05, 138.48, 136.77, 134.49,
134.20, 128.76, 126.71, 126.65, 126.57, 126.31, 124.43, 122.68, 120.74,
118.10, 117.90, 116.53, 111.14, 101.95. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 343.14 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.28"><title>
<italic toggle="yes">N</italic>-(2-Chlorophenyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide (<bold>9</bold>)</title><p>Compound <bold>9</bold> was obtained following general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-(2-chlorophenyl)&#173;thiourea
(118 mg, 0.63 mmol), affording it as a yellow solid (203 mg, 79%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.65 (br s, 1H), 8.84 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.47
(d, <italic toggle="yes">J</italic> = 4.8 Hz, 1H), 8.39 (d, <italic toggle="yes">J</italic> =
8.0 Hz, 1H), 8.10 (s, 1H), 7.51&#8211;739 (m, 3H), 7.31 (s, 1H),
7.11&#8211;7.07 (m, 1H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 164.26, 138.06, 137.44, 130.27, 130.14,
128.30, 128.19, 126.41, 124.21, 123.29, 122.49, 121.96, 116.60, 116.50,
111.65, 102.73. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 327.04
[M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.29"><title>
<italic toggle="yes">N</italic>-(Pyridin-2-yl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>10</bold>)</title><p>Compound <bold>10</bold> was
obtained following general
procedure C using <bold>44</bold> (100 mg, 0.42 mmol) and 2-pyridyl
thiourea (50 mg, 0.42 mmol) in anhydrous acetonitrile, affording it
as a yellow solid (109 mg, 69%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.76 (br s, 1H), 11.89 (br s, 1H),
8.98 (d, <italic toggle="yes">J</italic> = 7.2 Hz, 1H), 8.50 (d, <italic toggle="yes">J</italic> = 5.6 Hz, 1H), 8.39 (d, <italic toggle="yes">J</italic> = 3.6 Hz, 1H), 8.21 (s,
1H), 7.86 (t, <italic toggle="yes">J</italic> = 6.8 Hz, 1H), 7.53&#8211;7.49 (m,
1H), 7.47 (s, 1H) 7.25 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H), 7.07&#8211;7.04
(m, 1H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>,
100 MHz): &#948; 160.05, 151.22, 145.02, 142.91, 142.70, 140.01,
137.86, 134.81, 126.94, 121.07, 116.89, 116.48, 112.26, 111.58, 105.11.
MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 294.22 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.30"><title>4-(1<italic toggle="yes">H</italic>-Pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)-<italic toggle="yes">N</italic>-(<italic toggle="yes">p</italic>-tolyl)&#173;thiazol-2-amine
Hydrobromide
(<bold>11</bold>)</title><p>Compound <bold>11</bold> was obtained following
general procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and
1-(4-methylphenyl)-2-thiourea (105 mg, 0.63 mmol), affording it as
a pale-yellow solid (131 mg, 54%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.76 (br s, 1H), 10.30
(br s, 1H), 8.93 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.49 (d, <italic toggle="yes">J</italic> = 5.6 Hz, 1H), 8.11 (s, 1H), 7.57 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 2H), 7.53&#8211;7.49 (m, 1H), 7.22 (s, 1H), 7.13 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 2H), 2.22 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 164.20, 143.54, 141.89,
139.01, 137.19, 135.37, 131.00, 129.92 (2C), 126.99, 121.50, 117.94
(2C), 116.53, 111.95, 101.47, 20.83. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 307.13 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.31"><title>
<italic toggle="yes">N</italic>-(4-Methoxyphenyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>12</bold>)</title><p>Compound <bold>12</bold> was
obtained following general
procedure C using <bold>44</bold> (100 mg, 0.42 mmol) and 1-(4-methoxyphenyl)&#173;thiourea
(64 mg, 0.42 mmol), affording it as a yellowish solid (77 mg, 46%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.51 (br s, 1H), 10.17 (br s, 1H), 8.78 (d, <italic toggle="yes">J</italic> =
7.2 Hz, 1H), 8.42 (d, <italic toggle="yes">J</italic> = 6 Hz, 1H), 8.04 (s, 1H),
7.59 (d, <italic toggle="yes">J</italic> = 9.2 Hz, 2H), 7.44&#8211;7.40 (m, 1H),
7.14 (s, 1H), 6.94 (d, <italic toggle="yes">J</italic> = 9.2 Hz, 2H), 3.71 (s,
3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100
MHz): &#948; 164.80, 155.01, 143.63, 138.74, 134.77, 133.75, 126.55,
120.48, 119.91 (2C), 116.56, 114.82 (2C), 111.41, 111.39, 100.62,
55.71. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 323.14 [M
+ H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.32"><title>
<italic toggle="yes">N</italic>-(4-Chlorophenyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>13</bold>)</title><p>Compound <bold>13</bold> was
obtained following general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-(4-chlorophenyl)&#173;thiourea
(118 mg, 0.63 mmol), affording it as a yellowish solid (135 mg, 53%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.69 (br s, 1H), 10.48 (br s, 1H), 8.88 (d, <italic toggle="yes">J</italic> =
6.8 Hz, 1H), 8.47 (d, <italic toggle="yes">J</italic> = 5.2 Hz, 1H), 8.12 (s, 1H),
7.76 (d, <italic toggle="yes">J</italic> = 9.0 Hz, 2H), 7.51&#8211;7.48 (m, 1H),
7.37 (d, <italic toggle="yes">J</italic> = 9.0 Hz, 2H), 7.27 (s, 1H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 163.23,
144.41, 142.57, 140.53, 137.68, 134.85, 129.29 (2C), 126.94, 124.97,
121.13, 118.88 (2C), 116.59, 112.11, 102.02. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 327.14 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.33"><title>
<italic toggle="yes">N</italic>-(4-Nitrophenyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide (<bold>14</bold>)</title><p>Compound <bold>14</bold> was obtained following general
procedure C using <bold>44</bold> (100 mg, 0.42 mmol) and 1-(4-nitrophenyl)-2-thiourea
(83 mg, 0.42 mmol), affording it as a yellow solid (128 mg, 73%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.68 (br s, 1H), 11.17 (br s, 1H), 8.84 (d, <italic toggle="yes">J</italic> =
8.0 Hz, 1H), 8.45 (d, <italic toggle="yes">J</italic> = 5.6 Hz, 1H), 8.24 (d, <italic toggle="yes">J</italic> = 9.2 Hz, 2H), 8.18 (s, 1H), 7.95 (d, <italic toggle="yes">J</italic> = 9.2 Hz, 2H), 7.50&#8211;7.47 (m, 1H), 7.42 (s, 1H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 162.07,
147.37, 144.99, 143.32, 140.59, 138.32, 134.12, 127.10, 126.05 (2C),
120.64, 116.70, 116.66 (2C), 111.73, 103.67. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 338.23 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.34"><title>
<italic toggle="yes">N</italic>
<sup>1</sup>-(4-(1H-Pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-yl)-<italic toggle="yes">N</italic>,<sup>4</sup>
<italic toggle="yes">N</italic>
<sup>4</sup>-dimethylbenzene-1,4-diamine
Hydrobromide (<bold>15</bold>)</title><p>Compound <bold>15</bold> was
obtained following
general procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and
1-(4-dimethylamino)-thiourea (123 mg, 0.63 mmol), affording it as
a dark-green solid (87 mg, 33%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.59 (br s, 1H), 10.68 (br s, 1H),
8.81 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.44 (d, <italic toggle="yes">J</italic> = 5.2 Hz, 1H), 8.11 (s, 1H), 7.89 (d, <italic toggle="yes">J</italic> = 9.2 Hz,
2H), 7.73 (d, <italic toggle="yes">J</italic> = 9.2 Hz, 2H), 7.46&#8211;7.43 (m,
1H), 7.29 (s, 1H), 3.15 (s, 6H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 162.97, 144.73, 143.97,
142.19, 138.93, 136.46, 133.44, 126.69, 122.09, 120.29, 117.98 (2C),
116.57 (2C), 111.75, 102.06, 46.39 (2C). MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 336.19 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.35"><title>
<italic toggle="yes">N</italic>-(2-Methoxybenzyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide (<bold>17</bold>)</title><p>Compound <bold>17</bold> was obtained following general
procedure C using <bold>44</bold> (185 mg, 0.82 mmol) and <bold>45</bold> (160 mg, 0.82 mmol), affording it as a dark-yellow solid (180 mg,
66%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400
MHz): &#948; 12.33 (br s, 1H), 9.42 (br s, 1H), 8.39&#8211;8.34
(m, 2H), 8.10 (s, 1H), 7.37&#8211;7.25 (m, 3H), 7.06&#8211;7.03
(m, 2H), 6.95 (t, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 4.63 (s, 2H),
3.82 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 169.06, 157.56, 147.03, 142.46, 130.11, 129.76,
129.29, 126.64, 124.51, 120.77, 118.13, 116.89, 111.39, 99.55, 55.96,
45.04. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 337.32 [M
+ H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.36"><title>
<italic toggle="yes">N</italic>-(2-Chlorobenzyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>18</bold>)</title><p>Compound <bold>18</bold> was
obtained following general
procedure C using <bold>44</bold> (155 mg, 0.65 mmol) and <bold>46</bold> (130 mg, 0.65 mmol), affording it as a yellow solid (62 mg, 23%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.25 (br s, 1H), 8.94 (br s, 1H), 8.47 (d, <italic toggle="yes">J</italic> = 7.6
Hz, 1H), 8.35 (d, <italic toggle="yes">J</italic> = 4.8 Hz, 1H) 7.98 (s, 1H), 7.55&#8211;7.49
(m, 2H), 7.38&#8211;7.32 (m, 2H), 7.27&#8211;7.25 (m, 1H), 7.01
(s, 1H), 4.71 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 167.95, 140.71, 135.01, 132.38, 130.62,
129.32, 129.21, 129.05, 127.18, 125.44, 118.28, 115.93, 99.08, 45.90.
MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 341.13 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.37"><title>
<italic toggle="yes">N</italic>-(3-Chlorobenzyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>19</bold>)</title><p>Compound <bold>19</bold> was
obtained following general
procedure C using <bold>44</bold> (203 mg, 0.85 mmol) and <bold>47</bold> (170 mg, 0.85 mmol), affording it as a yellow solid (272 mg, 76%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.40 (br s, 1H), 9.24 (br s, 1H), 8.49 (d, <italic toggle="yes">J</italic> = 8.0
Hz, 1H), 8.38 (d, <italic toggle="yes">J</italic> = 3.2, 1H), 8.08 (s, 1H), 7.52
(s, 1H), 7.42&#8211;7.35 (m, 3H), 7.33&#8211;7.30 (m, 1H), 7.06
(s, 1H), 4.67 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.89, 145.78, 141.07, 140.73, 133.58,
131.58, 130.86, 127.92, 127.82, 126.75, 126.51, 119.05, 116.69, 99.88,
48.28. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 341.42 [M
+ H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.38"><title>
<italic toggle="yes">N</italic>-(4-Chlorobenzyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>20</bold>)</title><p>Compound <bold>20</bold> was
obtained following general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-(4-chlorobenzyl)&#173;thiourea
(127 mg, 0.63 mmol), affording it as a pale-yellow solid (147 mg,
55%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400
MHz): &#948; 12.43 (br s, 1H), 9.38 (br s, 1H), 8.46 (d, <italic toggle="yes">J</italic> = 7.2 Hz, 1H), 8.37 (d, <italic toggle="yes">J</italic> = 3.6 Hz, 1H),
8.09 (s, 1H), 7.45&#8211;7.40 (m, 4H), 7.32&#8211;7.28 (m, 1H),
7.07 (s, 1H), 4.65 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.95, 145.54, 141.04, 136.74, 132.53,
131.67, 130.01 (2C), 128.93 (2C), 126.77, 119.08, 116.76, 107.41,
100.14, 48.33. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 341.14
[M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.39"><title>
<italic toggle="yes">N</italic>-(4-Fluorobenzyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>21</bold>)</title><p>Compound <bold>21</bold> was
obtained following general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and <bold>48</bold> (116 mg, 0.63 mmol), affording it as a pale-yellow solid (52 mg,
20%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400
MHz): &#948; 12.35 (br s, 1H), 9.28 (br s, 1H), 8.47 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.38 (d, <italic toggle="yes">J</italic> = 4.8 Hz, 1H),
8.06 (s, 1H), 7.50&#8211;7.47 (m, 2H), 7.32&#8211;7.29 (m, 1H),
7.24&#8211;7.20 (m, 2H), 7.05 (s, 1H), 4.64 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.88,
162.01 (d, <sup>1</sup>
<italic toggle="yes">J</italic>
<sub>C&#8211;F</sub> = 241.5
Hz), 146.24, 141.56, 134.00, 131.08 (d, <italic toggle="yes">J</italic>
<sub>C&#8211;F</sub> = 6 Hz), 130.24 (d, <sup>3</sup>
<italic toggle="yes">J</italic>
<sub>C&#8211;F</sub> = 8.4 Hz, 2C), 126.45, 118.74, 116.74, 115.75 (d, <sup>2</sup>
<italic toggle="yes">J</italic>
<sub>C&#8211;F</sub> = 21.9 Hz, 2C), 99.77, 48.27. <sup>19</sup>F NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 377 MHz): &#948;
&#8722;115.09. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 325.13
[M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.40"><title>
<italic toggle="yes">N</italic>-(4-Methylbenzyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>22</bold>)</title><p>Compound <bold>22</bold> was
obtained following general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-(4-methylbenzyl)&#173;thiourea
(114 mg, 0.63 mmol), affording it as a yellow solid (166 mg, 66%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.34 (br s, 1H), 9.45 (br s, 1H), 8.42 (d, <italic toggle="yes">J</italic> = 8.0
Hz, 1H), 8.38 (d, <italic toggle="yes">J</italic> = 4.4 Hz, 1H), 8.08 (s, 1H),
7.33&#8211;7.28 (m, 3H), 7.20 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 2H),
7.06 (s, 1H), 4.62 (s, 2H), 2.29 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 169.01, 146.57, 142.01,
137.30, 134.20, 130.61, 129.56 (2C), 129.42, 128.18 (2C), 127.96,
126.62, 118.46, 116.84, 99.78, 48.99, 21.15. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 321.14 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.41"><title>
<italic toggle="yes">N</italic>-(4-Methoxybenzyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide (<bold>23</bold>)</title><p>Compound <bold>23</bold> was obtained following general
procedure C using <bold>44</bold> (150 mg, 0.63 mmol) and 1-(4-methoxybenzyl)&#173;thiourea
(124 mg, 0.63 mmol), affording it as a pale-yellow solid (199 mg,
76%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400
MHz): &#948; 12.39 (br s, 1H), 9.57 (br s, 1H), 8.43 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 8.38 (d, <italic toggle="yes">J</italic> = 5.2 Hz, 1H),
8.13 (s, 1H), 7.38 (d, <italic toggle="yes">J</italic> = 8.8 Hz, 2H), 7.32&#8211;7.29
(m, 1H), 7.09 (s, 1H), 6.95 (d, <italic toggle="yes">J</italic> = 8.8 Hz, 2H),
4.61 (s, 2H), 3.74 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.91, 159.30, 146.62, 142.11, 130.52,
129.72 (2C), 128.89, 126.76, 118.39, 116.88, 114.43 (2C), 106.34,
99.82, 55.59, 48.81. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 337.24 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.42"><title>
<italic toggle="yes">N</italic>-(4-Nitrobenzyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>24</bold>)</title><p>Compound <bold>24</bold> was
obtained following general
procedure C using <bold>44</bold> (102 mg, 0.43 mmol) and <bold>49</bold> (90 mg, 0.43 mmol), affording it as a green solid (127 mg, 68%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.46 (br s, 1H), 9.35 (br s, 1H), 8.50 (d, <italic toggle="yes">J</italic> = 8
Hz, 1H), 8.38 (d, <italic toggle="yes">J</italic> = 4 Hz, 1H), 8.12 (s, 1H), 7.48&#8211;7.41
(m, 4H), 7.33&#8211;7.25 (m, 1H), 7.09 (s, 1H), 4.70 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948;
168.72, 147.16, 146.93, 145.36, 140.53, 132.05, 128.96 (2C), 126.28,
124.05 (2C), 119.36, 116.53, 99.91, 48.05. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 352.23 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.43"><title>
<italic toggle="yes">N</italic>-(4-(Dimethylamino)&#173;benzyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide
(<bold>26</bold>)</title><p>Compound <bold>26</bold> was obtained following
general procedure C using <bold>44</bold> (198 mg, 0.83 mmol) and <bold>50</bold> (173 mg, 0.83 mmol), affording it as a light-blue solid
(70 mg, 20%). mp 155&#8211;156 &#176;C. <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.11 (br s, 1H), 9.01
(br s, 1H), 8.39 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.33 (d, <italic toggle="yes">J</italic> = 4.0 Hz, 1H), 7.97 (s, 1H), 7.39 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 2H), 7.25&#8211;7.22 (m, 1H), 7.10&#8211;7.09 (m, 2H),
6.97 (s, 1H), 4.55 (s, 2H), 2.99 (s, 6H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.58, 147.71, 147.69,
142.67, 132.87, 129.78, 129.75, 129.38, 125.76, 117.97, 116.63, 116.05,
115.63, 99.07, 48.43, 42.52. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 350.42 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.44"><title>
<italic toggle="yes">N</italic>-(Pyridin-4-ylmethyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide
(<bold>27</bold>)</title><p>Compound <bold>27</bold> was obtained following
general procedure C using <bold>44</bold> (143 mg, 0.60 mmol) and <bold>51</bold> (100 mg, 0.60 mmol), affording it as a yellowish solid
(170 mg, 73%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 11.86 (br s, 1H), 8.83 (d, <italic toggle="yes">J</italic> = 6.4 Hz, 2H), 8.57 (br s, 1H), 8.22&#8211;8.19 (m, 2H), 7.97 (d, <italic toggle="yes">J</italic> = 6.4 Hz, 2H), 7.75 (s, 1H), 7.09 (t, <italic toggle="yes">J</italic> = 6.4 Hz, 1H), 6.90 (s, 1H), 4.82 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 167.64, 159.88, 148.15,
145.29, 142.93 (2C), 142.55, 129.58, 125.17 (2C), 124.85, 117.88,
116.26, 110.63, 99.23, 47.40. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 308.20 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.45"><title>
<italic toggle="yes">N</italic>-((2-Chloropyridin-4-yl)&#173;methyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>28</bold>)</title><p>Compound <bold>28</bold> was
obtained following general procedure C using <bold>44</bold> (96 mg,
0.4 mmol) and <bold>52</bold> (80 mg, 0.4 mmol), affording it as a
yellow solid (89 mg, 53%). mp 164&#8211;165 &#176;C. <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.41
(br s, 1H), 8.90 (br s, 1H), 8.50 (d, <italic toggle="yes">J</italic> = 7.6 Hz,
1H), 8.36 (d, <italic toggle="yes">J</italic> = 5.2 Hz, 2H), 8.00 (s, 1H), 7.53
(s, 1H), 7.43 (d, <italic toggle="yes">J</italic> = 4.8 Hz, 1H), 7.31&#8211;7.28
(m, 1H), 7.02 (s, 1H), 4.66 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.58, 152.56, 150.87,
150.39, 144.68, 139.92, 132.73, 126.31, 123.04 (2C), 122.23 (2C),
119.74, 116.48, 100.21, 47.07. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 342.23 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.46"><title>
<italic toggle="yes">N</italic>-(Pyrimidin-2-ylmethyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide
(<bold>29</bold>)</title><p>Compound <bold>29</bold> was obtained following
general procedure C using <bold>44</bold> (185 mg, 0.77 mmol) and <bold>53</bold> (130 mg, 0.77 mmol), affording it as a light-green solid
(220 mg, 73%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.39 (br s, 1H), 9.58 (br s, 1H), 8.84 (d, <italic toggle="yes">J</italic> = 5.2 Hz, 2H), 8.43 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 1H),
8.37 (d, <italic toggle="yes">J</italic> = 5.2 Hz, 1H), 8.11 (s, 1H), 7.47 (t, <italic toggle="yes">J</italic> = 5.2 Hz, 1H), 7.32&#8211;7&#8211;7.29 (m, 1H), 7.10
(s, 1H), 4.94 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.93, 165.06, 157.45 (2C), 145.78,
141.20, 137.13, 130.16, 126.00, 120.12, 117.93, 116.18, 106.14, 99.30,
50.30. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 309.30 [M
+ H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.47"><title>
<italic toggle="yes">N</italic>-(Pyrazin-2-ylmethyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide
(<bold>30</bold>)</title><p>Compound <bold>24</bold> was obtained following
general procedure C using <bold>44</bold> (185 mg, 0.77 mmol) and <bold>54</bold> (130 mg, 0.77 mmol), affording it as a brownish solid (220
mg, 73%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>,
400 MHz): &#948; 12.46 (br s, 1H), 9.27 (br s, 1H), 8.78 (s, 1H),
8.64 (s, 1H), 8.57 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H), 8.51 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.38 (d, <italic toggle="yes">J</italic> = 5.0 Hz, 1H),
8.10 (s, 1H), 7.32 (dd, <sup>1</sup>
<italic toggle="yes">J</italic> = 5.0 Hz, <sup>2</sup>
<italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.08 (s, 1H), 4.86 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
169.04, 153.32, 145.26, 144.53, 144.26, 144.07, 140.59, 132.00, 126.64,
119.28, 116.66, 100.10, 48.32. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 309.30 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.48"><title>
<italic toggle="yes">N</italic>-Benzyl-<italic toggle="yes">N</italic>-methyl-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>31</bold>)</title><p>Compound <bold>31</bold> was
obtained following general procedure C using <bold>44</bold> (225
mg, 0.94 mmol) and <bold>55</bold> (170 mg, 0.94 mmol), affording
it as a yellow solid (118 mg, 31%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.50 (br s, 1H), 8.70
(d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.39 (d, <italic toggle="yes">J</italic> =
5.2 Hz, 1H), 8.05 (s, 1H), 7.37&#8211;7.29 (m, 5H), 7.28&#8211;7.26
(m, 1H), 7.10 (s, 1H), 4.79 (s, 2H), 3.12 (s, 3H). <sup>13</sup>C
NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 170.09,
139.09, 137.12, 133.63, 129.07 (2C), 127.96 (2C), 127.92, 126.57,
120.38, 116.52, 100.40, 56.41, 39.16. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 321.23 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.49"><title>
<italic toggle="yes">N</italic>-Phenethyl-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide (<bold>32</bold>)</title><p>Compound <bold>32</bold> was obtained following general
procedure C using <bold>44</bold> (259 mg, 1.08 mmol) and <bold>56</bold> (195 mg, 1.08 mmol), affording it as a light-yellow solid (321 mg,
74%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400
MHz): &#948; 12.29 (br s, 1H), 9.23 (br s, 1H), 8.40&#8211;8.35
(m, 2H), 8.06 (s, 1H), 7.33&#8211;7.21 (m, 6H), 7.04 (s, 1H), 3.69
(t, <italic toggle="yes">J</italic> = 7.0 Hz, 2H), 2.96 (t, <italic toggle="yes">J</italic> =
7.0 Hz, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 168.89, 147.28, 142.69, 138.91, 129.85, 129.28
(2C), 128.88 (2C), 126.91, 126.60, 118.03, 116.83, 99.43, 47.43, 34.59.
MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 321.23 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.50"><title>
<italic toggle="yes">N</italic>-(4-(1<italic toggle="yes">H</italic>-Pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-yl)&#173;benzamide
Hydrobromide (<bold>33</bold>)</title><p>Compound <bold>33</bold> was
obtained following
general procedure C using <bold>44</bold> (186 mg, 0.78 mmol) and <bold>57</bold> (140 mg, 0.78 mmol), affording it as a yellowish solid
(220 mg, 70%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.59 (br s, 2H), 9.00 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.46 (d, <italic toggle="yes">J</italic> = 4.0 Hz, 1H), 8.10 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 2H), 7.63&#8211;7.52 (m, 5H), 7.47&#8211;7.44
(m, 1H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>,
100 MHz): &#948; 165.64, 158.66, 143.94, 143.17, 138.37, 134.68,
133.09, 132.49, 129.04, 128.62, 126.34, 120.94, 116.46, 117.77, 107.02.
MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 321.21 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.51"><title>
<italic toggle="yes">N</italic>-Benzyl-4-(5-bromo-1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>38</bold>)</title><p>Compound <bold>38</bold> was
obtained following general
procedure C using <bold>74</bold> (140 mg, 0.44 mmol) and <italic toggle="yes">N</italic>-benzyl thiourea (70 mg, 0.44 mmol), affording it as a
yellow solid (98 mg, 48%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.37 (br s, 1H), 9.78 (br s, 1H),
8.46 (d, <italic toggle="yes">J</italic> = 2.3 Hz, 1H), 8.37 (d, <italic toggle="yes">J</italic> = 2.2 Hz t, 1H), 8.12 (d, <italic toggle="yes">J</italic> = 2.8 Hz, 1H), 7.45&#8211;7.38
(m, 4H), 7.32 (t, <italic toggle="yes">J</italic> = 7 Hz, 1H), 7.13 (s, 1H), 4.69
(s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>,
400 MHz): &#948; 169.14, 147.21, 144.19, 136.90, 130.39, 129.10 (2C),
128.20, 128.18 (2C), 127.99, 118.85, 112.27, 100.20, 49.37. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 387.10 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.52"><title>
<italic toggle="yes">N</italic>-Benzyl-5-methyl-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine Hydrobromide (<bold>39</bold>)</title><p>Compound <bold>39</bold> was obtained following general
procedure C using <bold>75</bold> (137 mg, 0.51 mmol) and <italic toggle="yes">N</italic>-benzyl thiourea (80 mg, 0.51 mmol), affording it as a
yellowish solid (85 mg, 42%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.36 (br s, 1H), 9.89 (br s, 1H),
8.34 (d, <italic toggle="yes">J</italic> = 4.9 Hz, 1H), 8.01 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.85 (s, 1H), 7.41 (d, <italic toggle="yes">J</italic> = 4.6 Hz,
4H), 7.36&#8211;7.32 (m, 1H), 7.21&#8211;7.18 (m, 1H), 4.65 (s,
2H), 2.24 (s, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 166.02, 146.58, 142.32, 136.35, 129.35,
129.31, 128.53 (2C), 127.60, 127.55 (2C), 127.10, 119.44, 118.68,
116.12, 113.60, 48.20, 11.58. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 321.19 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.53"><title>
<italic toggle="yes">N</italic>-Benzyl-4-(5-bromo-1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)-5-methylthiazol-2-amine
Hydrobromide (<bold>41</bold>)</title><p>Compound <bold>41</bold> was
obtained following
general procedure C using <bold>76</bold> (120 mg, 0.36 mmol) and <italic toggle="yes">N</italic>-benzyl thiourea (60 mg, 0.36 mmol), affording it as a
light-brown solid (138 mg, 80%). mp 254&#8211;256 &#176;C. <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.43
(br s, 1H), 9.90 (br s, 1H), 8.37 (d, <italic toggle="yes">J</italic> = 2.2 Hz,
1H), 8.24 (s, 1H), 7.90 (d, <italic toggle="yes">J</italic> = 2.8 Hz, 1H), 7.45&#8211;7.42
(m, 4H), 7.40&#8211;7&#8211;32 (m, 1H), 4.64 (s, 2H), 2.24 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948;
166.62, 146.84, 144.07, 136.90, 136.84, 130.73, 129.11 (2C), 128.20,
128.06 (2C), 121.62, 120.34, 114.54, 111.87, 48.79, 12.09. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 399.24 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.54"><title>5-Methyl-<italic toggle="yes">N</italic>-(pyridin-4-ylmethyl)-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>42</bold>)</title><p>Compound <bold>42</bold> was
obtained following general procedure C using <bold>75</bold> (152
mg, 0.6 mmol) and <bold>51</bold> (100 mg, 0.6 mmol), affording it
as a pinkish solid (84 mg, 35%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 11.87 (br s, 1H), 8.82 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 2H), 8.43 (br s, 1H), 8.19 (dd, <sup>1</sup>
<italic toggle="yes">J</italic> = 4.7 Hz, <sup>2</sup>
<italic toggle="yes">J</italic> = 1.7
Hz, 1H), 7.92 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 2H), 7.82 (dd, <sup>1</sup>
<italic toggle="yes">J</italic> = 7.9 Hz, <sup>2</sup>
<italic toggle="yes">J</italic> = 1.7 Hz, 1H), 7.57 (s, 1H), 6.96 (dd, <sup>1</sup>
<italic toggle="yes">J</italic> = 7.9 Hz, <sup>2</sup>
<italic toggle="yes">J</italic> = 4.7 Hz, 1H), 4.75 (s,
2H), 2.30 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 164.35, 159.59, 147.70, 143.47 (2C), 142.70,
139.91, 130.37, 124.87 (2C), 124.74, 119.32, 115.83, 113.39, 109.25,
47.15, 12.37. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 322.23
[M + H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.55"><title>
<italic toggle="yes">N</italic>-((2-Chloropyridin-4-yl)&#173;methyl)-5-methyl-4-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)&#173;thiazol-2-amine
Hydrobromide (<bold>43</bold>)</title><p>Compound <bold>43</bold> was
obtained following general procedure C using <bold>75</bold> (101
mg, 0.40 mmol) and <bold>52</bold> (80 mg, 0.40 mmol), affording it
as a yellow solid (120 mg, 69%). mp 190&#8211;191 &#176;C. <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948; 12.25
(br s, 1H), 8.95 (br s, 1H), 8.42 (d, <italic toggle="yes">J</italic> = 5.2 Hz,
1H), 8.33 (dd, <sup>1</sup>
<italic toggle="yes">J</italic> = 5.0 Hz, <sup>2</sup>
<italic toggle="yes">J</italic> = 1.2 Hz, 1H), 8.07 (d, <italic toggle="yes">J</italic> = 8.0
Hz, 1H), 7.75 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H), 7.54 (s, 1H),
7.44 (dd, <sup>1</sup>
<italic toggle="yes">J</italic> = 5.0 Hz, <sup>2</sup>
<italic toggle="yes">J</italic> = 1.4 Hz, 1H), 7.18 (dd, <sup>1</sup>
<italic toggle="yes">J</italic> = 5.0 Hz, <sup>2</sup>
<italic toggle="yes">J</italic> = 8.0 Hz, 1H), 4.64 (s,
2H), 2.32 (s, 3H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 166.02, 151.90, 150.94, 150.48, 141.19,
131.84, 131.32, 127.02, 122.95, 122.07, 120.36, 116.28, 114.63. 46.86.
12.21. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 356.15 [M
+ H]<sup>+</sup>.</p></sec><sec id="sec4.1.3.56"><title>
<italic toggle="yes">N</italic>-Benzyl-5-(1<italic toggle="yes">H</italic>-pyrrolo&#173;[2,3-<italic toggle="yes">b</italic>]&#173;pyridin-3-yl)-1,3,4-thiadiazol-2-amine
(<bold>40</bold>)</title><p>In a pressure tube, a mixture of <bold>77</bold> (100
mg, 0.7 mmol) and <bold>78</bold> (317 mg, 1.75 mmol) was dissolved
in trifluoroacetic acid (2.5 mL), refluxed for 3 h, and monitored
by TLC. After completion, the reaction was cooled down to room temperature
and diluted with water (3 mL). Then, 30% ammonia aqueous solution
was added dropwise until pH = 8. The resulting precipitate was filtered,
washed with EtOAc, and dried to obtain the pure product <bold>40</bold> as a yellow solid (156 mg, 71%). mp 265&#8211;267 &#176;C. <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 400 MHz): &#948;
12.17 (br s, 1H), 8.43 (dd, <sup>1</sup>
<italic toggle="yes">J</italic> = 7.8 Hz, <sup>2</sup>
<italic toggle="yes">J</italic> = 1.5 Hz, 1H), 8.32&#8211;8.26 (m, 2H),
8.00 (s, 1H), 7.40&#8211;7.33 (m, 4H), 7.28&#8211;7.19 (m, 2H),
4.54 (d, <italic toggle="yes">J</italic> = 4.8 Hz, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, 100 MHz): &#948; 166.59, 152.07, 149.08,
144.43, 139.25, 129.54, 128.80 (2C), 127.97 (2C), 127.53, 127.30,
117.34, 117.10, 106.60, 48.51. MS [ESI+] <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: 308.09 [M + H]<sup>+</sup>.</p></sec></sec></sec><sec id="sec4.2"><title>Kinase Assays</title><p>GSK-3&#946; and FYN&#945; kinase assays
were run in 384-well microplates (OptiPlate-384, White, PerkinElmer)
in a total reaction volume of 20 &#956;L. The inhibitory potency
against human recombinant GSK-3&#946; and FYN&#945; (Carna Biosciences)
was evaluated using the LANCE Ultra (PerkinElmer) time-resolved fluorescence
resonance energy transfer (TR-FRET) by measuring the phosphorylation
of the ULight-labeled substrate, according to the manufacturer&#8217;s
instructions. The synthetic peptide surrounding Ser641 of human muscle
glycogen synthase (ULight-GS (Ser641/pSer657)) and the synthetic 28-amino
acid peptide containing eight Tyr residues placed in different amino
acid contexts (ULightTM-TK (PT66)) were selected as specific substrates
for GSK-3&#946; and FYN&#945;, respectively. Briefly, test compounds
and staurosporine (reference compound) or DMSO (control) are mixed
with the enzyme (GSK-3&#946;: 2 nM and FYN&#945;: 1 nM) in a buffer
containing 50 mM HEPES (pH 7.5), 1 mM EGTA, 10 mM MgCl<sub>2</sub>, 2 mM DTT, and 0.01% Tween-20. The reaction is initiated by adding
50 nM of the substrate and ATP at a final concentration, determined
experimentally for each new ATP stock solution prepared, near the <italic toggle="yes">K</italic>
<sub>m</sub> value of the enzyme for ATP (e.g., GSK-3&#946;:
1.2 &#956;M or FYN-&#945;: 8 &#956;M), and the mixture is incubated
for 60 or 90 min, respectively, at 23 &#176;C. Following incubation,
the reaction is stopped by adding 6 mM EDTA. After 5 min, the antiphospho
antibody labeled with europium chelate is added. After 1 more hour,
the kinase reaction is monitored by irradiation at 320 nm and the
fluorescence measured at 615 and 665 nm, using EnVision 2014 Multilabel
Reader (PerkinElmer). The calculated signal ratio at 665/615 nm is
proportional to the extent of ULight-substrate phosphorylation. The
compounds were tested at 11 different concentrations ranging from
3 nM up to 100 &#956;M in triplicate. For a few compounds with poor
solubility or potency, percentage of inhibition at one concentration
(50 &#956;M) was determined. The results were expressed as a percent
inhibition of the control enzyme activity.</p><p>To study the GSK-3&#946;
and FYN&#945; kinetics, the reaction mixture, varying concentrations
of ATP (0.75, 1.5, 3, 6, and 12 &#956;M or 1.5, 3, 6, 12, and 24
&#956;M for GSK-3&#946; and FYN&#945;, respectively) versus test
compound 43 (0.75 &#956;M and 4.5 &#956;M against GSK-3&#946; and
0.05 and 0.3 &#956;M against FYN&#945;) were incubated for 5, 15,
30, and 60 min (and 90 min for FYN&#945; only) at 23 &#176;C, followed
by the addition of 6 mM EDTA and the antiphospho-GS or antiphospho-TK
antibodies, for GSK-3&#946; and FYN&#945; respectively, according
to the manufacturer&#8217;s protocol. Initial velocities (<italic toggle="yes">V</italic>
<sub>0</sub>) were determined and fitted to the Michaelis&#8211;Menten
equation. To directly visualize the compound <bold>43</bold> inhibition
mode, a Lineweaver&#8211;Burk plot was generated according to the
values obtained from the Michaelis&#8211;Menten analysis. The slope
corresponded to <italic toggle="yes">K</italic>
<sub>m</sub>/<italic toggle="yes">V</italic>
<sub>max</sub>, the intercept on the vertical axis corresponded to 1/<italic toggle="yes">V</italic>
<sub>max</sub>, and the intercept on the horizontal axis
corresponded to &#8722;1/<italic toggle="yes">K</italic>
<sub>m</sub>. Moreover,
at the reciprocal of the smallest value of substrate concentration
(<italic toggle="yes">X</italic> = 1/[<italic toggle="yes">S</italic>
<sub>min</sub>]) was associated
a value of <italic toggle="yes">Y</italic> representing the equation <italic toggle="yes">Y</italic> = (1/<italic toggle="yes">V</italic>
<sub>max</sub>)&#173;(1.0 + <italic toggle="yes">K</italic>
<sub>m</sub>/[<italic toggle="yes">S</italic>
<sub>min</sub>]). Graphs and data analysis
were performed by using GraphPad Prism 8 software. The kinase selectivity
profiles of compounds <bold>41</bold> and <bold>43</bold> were evaluated
at single concentration (i.e., 10.0 &#956;M) using the gold standard
radiometric kinase assay through the Eurofins KinaseProfiler platform.</p><sec id="sec4.2.1"><title>Analysis
of the Biological Data</title><p>Dose&#8211;response
curves were run in at least three independent experiments, performed
in three technical replicates. IC<sub>50</sub> values (concentrations
causing half-maximal enzyme inhibition) were determined by nonlinear
regression analysis of the Log&#173;[concentration]/response curves generated
with mean replicate values using a four parameter Hill equation curve
fitting with GraphPad Prism 8 (GraphPad Software Inc., CA-USA).</p></sec></sec><sec id="sec4.3"><title>Computational Studies</title><p>The structures 2DQ7<xref rid="ref44" ref-type="bibr"/> for FYN and 6Y9R<xref rid="ref45" ref-type="bibr"/> for GSK-3&#946;
were retrieved from the Protein Data Bank and aligned
for comparative analysis of docking results. Subsequently, the proteins
underwent preparation using the Protein Preparation Wizard tool within
the Schr&#246;dinger suite (Maestro Version 13.1.141, MMshare Version
5.7.141, Release 2022-1), employing default parameters and the OPLS4
force field for minimization.</p><p>Grids for docking were constructed
using Glide, with a center on staurosporine for FYN and 1<italic toggle="yes">H</italic>-indazole-3-carboxamide inhibitor for GSK-3&#946;. The grid size
was chosen to accommodate ligands of up to 20 &#197; in length. Ligands
were sketched in Maestro and subjected to ligand preparation using
the LigPrep tool, employing the OPLS4 force field for minimization.
Various protonation states at pH 7 &#177; 2, as well as tautomers
and stereoisomers, were generated. The prepared ligand library underwent
molecular docking on both proteins using Glide in SP mode.</p><p>Subsequently,
complexes obtained from traditional docking for compounds <bold>28</bold>, <bold>40</bold>, <bold>41</bold>, and <bold>43</bold> were
utilized as a starting point for molecular dynamics simulations. Each
system was built using the System Builder tool, employing the TIP4P
solvation model within an orthorhombic box with a 10 &#197; margin.
Automatic neutralization and the OPLS4 force field were applied.</p><p>Molecular dynamics simulations were conducted with Desmond for
100 ns, saving coordinates every 100 ps at 300 K and 1.01325 bar (<italic toggle="yes">NPT</italic> ensemble). Before the simulation, each system was relaxed
using the default protocol within the software. Trajectory analysis
was performed using the Simulation Interaction Diagram tool. Binding
mode images were generated using PyMOL (ver. 2.5.0), while interaction
profiles over time were extracted from the report generated by the
Simulation Interaction Diagram tool, focusing on the last 50 ns of
simulation.</p></sec><sec id="sec4.4"><title>Biological Evaluation</title><sec id="sec4.4.1"><title>Cell Viability in Primary
Cerebellar Granule Cells (CGNs)</title><p>Primary cerebellar granule
cells were dissociated from cerebella
and plated on 96-well plates, previously coated with 10 &#956;g/mL
poly-<sc>l</sc>-lysine, at a density of 1.2 &#215; 10<sup>5</sup> cells/0.2
mL medium/well in BME supplemented with 10% heat-inactivated FBS (Life
Technologies), 2 mmol/L glutamine, 100 &#956;mol/L gentamicin sulfate,
and 25 mM KCl (all from Sigma-Aldrich). Sixteen hours later, 10 &#956;M
cytosine arabinofuranoside (Sigma-Aldrich) was added to avoid glial
proliferation. After 7 days <italic toggle="yes">in vitro</italic>, differentiated
neurons were shifted to serum-free BME medium and exposed to increasing
concentrations (5 &#956;M, 10 &#956;M, 25 &#956;M) of compounds
of interest for 24 h. Then, cell viability was evaluated through the
MTT assay.<xref rid="ref39" ref-type="bibr"/>
</p></sec><sec id="sec4.4.2"><title>Neuroprotection in CGNs</title><p>To evaluate the neuroprotective
effect of our compounds, we tested increasing concentrations (5 &#956;M,
10 &#956;M, 25 &#956;M) of compounds of interest in differentiated
CGNs switched to serum-free BME medium with 5 mM KCl (serum-potassium
deprivation) for 48 h to mimic in vitro the naturally occurring death
of granule cells.<xref rid="ref39" ref-type="bibr"/> Neuroprotection was
evaluated through MTT assay.<xref rid="ref46" ref-type="bibr"/>
</p></sec><sec id="sec4.4.3"><title>MTT Assay</title><p>For MTT assay, thiazolyl blue was added to
the culture medium at a final concentration of 0.1 mg/mL. Following
a 20 min incubation at 37 &#176;C in the dark, the MTT precipitate
was dissolved in 0.1 M Tris&#8211;HCl pH 7.5 buffer containing 5%
Triton X-100 (all from Sigma-Aldrich) and absorbance was read at 570
nm in a microplate spectrophotometric reader (Bio-Rad).</p></sec><sec id="sec4.4.4"><title>Immunomodulation
in N9 Cell Line</title><p>N9 microglial cells
were plated at a density of 2.5 &#215; 10<sup>5</sup> cells/35 mm
&#216; dish in serum-free DMEM High Glucose (Life Technologies) and
pretreated (2 h) with increasing concentrations of compounds (2.5
and 5 &#956;M) in the presence of 100 ng/mL LPS for 24 h. The microglial
phenotype was evaluated through Western blot analysis of the pro-inflammatory
iNOS and anti-inflammatory-TREM2 markers.</p></sec><sec id="sec4.4.5"><title>Neurosphere Assays</title><p>NSCs were initially obtained by
SVZ microdissection of 6 months-old C57BL/6N wild-type male mice (<italic toggle="yes">Mus musculus</italic>) and routinely cultured in suspension
in DMEM-F12 (Gibco; ThermoFisher Scientific, Waltham, MA, USA) supplemented
with 2 mM glutamine, 10 &#956;g/mL insulin from bovine pancreas (Sigma-Aldrich;
St Louis, MO, USA), 20 ng/mL epidermal growth factor (EGF; PeproTech
EC, London, UK), 20 ng/mL fibroblast growth factor-2 (FGF2; PeproTech),
1% N2 (ThermoFisher Scientific), 1% B27 (ThermoFisher Scientific),
10 units/mL penicillin, and 10 &#956;g streptomycin.<xref rid="ref47" ref-type="bibr"/>
</p><p>To investigate the effect of compounds of interest
in neurospheres&#8217; growth rate, single spheres were plated in
suspension in 96-well plates (5 &#215; 10<sup>3</sup> cells/well)
in the presence of compounds (0.1 &#956;M, 1 &#956;M, and 5 &#956;M)
in complete DMEM F-12 culture medium. One image/well was acquired
every day by using the Sartorius Incucyte Live-Cell Analysis System
and evaluated through the Brightfield Spheroid Analysis Software Module.
Only aggregates with areas larger than 400 &#956;m<sup>2</sup> were
considered for statistical analysis.</p><p>To assess the effect of
compounds of interest in NSCs differentiation,
30 spheres were plated on 13 mm glass coverslips, previously coated
with Matrigel matrix (Corning; New York, USA), in complete DMEM F-12
medium, and treated with 1 &#956;M of compounds of interest. After
7DIV, neurospheres were fixed for 20 min with 4% PFA in PBS 0.1% pH
7.4. Fixed neurospheres were permeabilized in 0.1% Triton/PBS and
nonspecific sites were blocked for 1 h with 0.1% Triton/PBS and 5%
normal goat serum (Sigma-Aldrich; St Louis, MO, USA). Cells were then
incubated overnight at 4 &#176;C with the following primary antibodies:
Anti-Doublecortin DCX (Abcam, Cambridge, UK), GFAP (Dakopatts), OLIG2
(Santa Cruz Biotechnology), 1:500 dilution in 0.1% Triton/PBS with
2% normal goat serum. After 3 washes in 0.1% Triton/PBS, specific
secondary antibodies were added for 2 h at RT in the dark: Donkey
anti-Mouse IgG Alexafluor 555 (Abcam, Cambridge, UK), Goat anti-Rabbit
IgG Alexafluor 555 (Abcam, Cambridge, UK), 1:1000 dilution in 0.1%
Triton/PBS with 2% normal goat serum. Following 3 washes in 0.1% Triton/PBS,
nuclei were stained with DAPI (2 &#956;g/mL, Sigma-Aldrich) for 5
min. Glass coverslips were mounted by using Ultracruz Aqueous Mounting
Medium with DAPI (Santa Cruz Biotechnology). Neurospheres confocal
images were obtained with a Nikon EZ-C1 microscope (60&#215; objective)
and the z-stack function (1024 steps and 1 &#956;m thickness layers;
40 total stacks). 3D image reconstruction was performed by using Fiji
ImageJ2 software, z-project plugin, and selecting the sum stacks&#8217;
function. Fluorescence intensity index was estimated as the ratio
of markers&#8217; positive cells intensity/total cells fluorescence
intensity stained with DAPI per ROI.<xref rid="ref48" ref-type="bibr"/>
</p></sec><sec id="sec4.4.6"><title>Statistical Analysis</title><p>Data were analyzed by using the
GraphPad Prism8, San Diego, CA, United States, software and expressed
as the mean &#177; standard error of independent experiments. One-way
ANOVA followed by Dunnett&#8217;s post hoc was used to compare the
means between control and treated cells. Only <italic toggle="yes">p</italic>-values
&lt; 0.05 were considered statistically significant.</p></sec></sec><sec id="sec4.5"><title>BBB Permeability</title><p>BBB permeability assay was conducted
as described in Albertini et al.<xref rid="ref39" ref-type="bibr"/> The
brain microvascular endothelial cells (hCMEC/D3) were seeded at the
density of 5 &#215; 10<sup>4</sup> cells per cm<sup>2</sup> in the
upper compartment of Transwell filters (polyester, pore size 0.4 &#956;m,
12-well tissue culture transwell; Corning), precoated with rat tail
collagen type I (0.1 mg/mL; Roche). They were grown for 7 days up
to confluence in Endothelial Cell Growth Medium 2 (Promocell), supplemented
with penicillin/streptomycin 100 U/mL, in a humidified, 5% CO<sub>2</sub> incubator at 37 &#176;C. Confluent monolayers were washed
in prewarmed HBSS buffer, and the selected compounds were added to
the apical (AP) side at a concentration of 100 &#956;M. The permeability
coefficient of tetramethylrhodamine isothiocyanate (TRITC)-dextran
(average mol wt 4400; Sigma-Aldrich), considered as a parameter of
paracellular transport and of tight junction integrity,<xref rid="ref49" ref-type="bibr"/> was measured. Samples (100 &#956;L) were collected
from the BL side at different time points (15, 30, 60, and 90 min)
and then replaced with the corresponding volume of HBSS buffer. TRITC-dextran
flux had initially been monitored over a duration of 300 min but,
at incubation times longer than 90 min, cytotoxic effects on hCMEC/D3
cells were observed in accordance with a previous report.<xref rid="ref50" ref-type="bibr"/> The concentration of compounds was determined
using a Ultimate 3000 HPLC system (ThermoFisher) with UV&#8211;vis
detection at the maximum absorption wavelength of each compound except
for inulin as determined by a spectrophotometric method using a Tecan
Sunrise absorbance microplate reader.<xref rid="ref51" ref-type="bibr"/> The amount of TRITC-dextran was quantified using an Infinite 200
PRO microplate reader (Tecan) with excitation and emission at 540
and 590 nm, respectively. The permeability coefficient (Papp) was
calculated as follows: Papp = (&#916;<italic toggle="yes">Q</italic>/&#916;<italic toggle="yes">t</italic>)/(<italic toggle="yes">C</italic>
<sub>[donor]</sub> &#215; <italic toggle="yes">A</italic>), where &#916;<italic toggle="yes">Q</italic>/&#916;<italic toggle="yes">t</italic> represents the permeation rate (mol/s), <italic toggle="yes">C</italic>
<sub>[donor]</sub> is the initial compound concentration in the donor compartment at
time 0 (mol/cm<sup>3</sup>), and A represents the surface area of
the filter (1.12 cm<sup>2</sup>).</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c00629_si_001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sifile2" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c00629_si_002.csv" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><p>This research was supported by the Italian Ministry
of University and Research (MUR), PRIN 2017(2017MT3993_007). The Sartorius
Incucyte Live-Cell Analysis System was provided by Centre for Applied
Biomedical Research&#58872;CRBA, University of Bologna-Sant&#8217;Orsola.
The authors acknowledge Dr. Tiziano Bandiera for fruitful discussion
and collaboration.</p></ack><notes id="notes1" notes-type="si"><p>The Supporting Information
is
available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00629?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00629</ext-link>.<list list-type="simple" id="silist"><list-item><p>Supplementary chemistry
material; 3D binding poses of
compounds <bold>28</bold> and <bold>43</bold>; Western blot analysis
of Fyn and GSK-3&#946; expression in exploited cell lines; neurotoxicity
and neuroprotective profiles of compounds <bold>21</bold>, <bold>27</bold>, <bold>33</bold>, <bold>38</bold>, <bold>39</bold> and <bold>42</bold>; NPC proliferation analysis for compounds <bold>27</bold>, <bold>39</bold> and <bold>42</bold>; physicochemical parameters
of compounds <bold>28</bold> and <bold>43</bold>; permeability coefficients
of compounds <bold>28</bold> and <bold>43</bold>; kinase inhibition
profiles of compounds <bold>41</bold> and <bold>43</bold>; <sup>1</sup>H, <sup>13</sup>C NMR spectra, and UHPLC-MS traces of compounds <bold>26</bold>, <bold>28</bold>, <bold>40</bold>, <bold>41</bold>, and <bold>43</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item><list-item><p>Molecular formula strings containing SMILES string and
associated biochemical and biological data (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00629/suppl_file/jm5c00629_si_002.csv" ext-link-type="uri">CSV</ext-link>)</p></list-item></list>
</p></notes><notes id="notes3" notes-type="author-present-addresses"><label>&#8711;</label><p>Structural
Biophysics Facility, Istituto Italiano di Tecnologia,
Via Morego, 30, 16163 Genova, Italy</p></notes><notes id="notes2" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><glossary><def-list specific-use="delimiter-char:, " id="dl1"><title>Abbreviations</title><def-item><term>ANOVA</term><def><p>analysis
of variance</p></def></def-item><def-item><term>APP</term><def><p>amyloid precursor protein</p></def></def-item><def-item><term>BBB</term><def><p>blood&#8211;brain
barrier</p></def></def-item><def-item><term>BME</term><def><p>basal
medium eagle</p></def></def-item><def-item><term>CGN</term><def><p>cerebellar granule neurons</p></def></def-item><def-item><term>CNS</term><def><p>central nervous system</p></def></def-item><def-item><term>DAPI</term><def><p>4&#8242;,6-diamidino-2-phenylindole</p></def></def-item><def-item><term>DCM</term><def><p>dichloromethane</p></def></def-item><def-item><term>DCX</term><def><p>doublecortin</p></def></def-item><def-item><term>DMEM</term><def><p>Dulbecco&#8217;s modified
eagle medium</p></def></def-item><def-item><term>DMSO</term><def><p>dimethyl sulfoxide</p></def></def-item><def-item><term>DTT</term><def><p>1,4-dithiothreitol</p></def></def-item><def-item><term>Fyn</term><def><p>Fyn proto-oncogene kinase</p></def></def-item><def-item><term>EDTA</term><def><p>ethylenediaminetetraacetic acid</p></def></def-item><def-item><term>EGTA</term><def><p>egtazic acid</p></def></def-item><def-item><term>FBS</term><def><p>fetal bovine serum</p></def></def-item><def-item><term>GAPDH</term><def><p>glyceraldehyde-3-phosphate
dehydrogenase</p></def></def-item><def-item><term>GFAP</term><def><p>glial fibrillary acidic protein</p></def></def-item><def-item><term>GSK-3&#946;</term><def><p>glycogen synthase kinase 3&#946;</p></def></def-item><def-item><term>HBSS</term><def><p>Hanks&#8217; balanced
salt solution</p></def></def-item><def-item><term>HPLC</term><def><p>high-performance liquid chromatography</p></def></def-item><def-item><term>iNOS</term><def><p>inducible nitric oxide synthase</p></def></def-item><def-item><term>LPS</term><def><p>lipopolysaccharide</p></def></def-item><def-item><term>MTT</term><def><p>3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide</p></def></def-item><def-item><term>MW</term><def><p>microwave</p></def></def-item><def-item><term>NFT</term><def><p>neurofibrillary
tangles</p></def></def-item><def-item><term>NMR</term><def><p>nuclear
magnetic resonance</p></def></def-item><def-item><term>NPC</term><def><p>neural progenitor cell</p></def></def-item><def-item><term>PBS</term><def><p>phosphate-buffered saline</p></def></def-item><def-item><term>OLIG2</term><def><p>oligodendrocyte transcription factor 2</p></def></def-item><def-item><term>SAR</term><def><p>structure&#8211;activity
relationship</p></def></def-item><def-item><term>SVZ</term><def><p>subventricular zone</p></def></def-item><def-item><term>TLC</term><def><p>thin-layer chromatography</p></def></def-item><def-item><term>TMS</term><def><p>tetramethyl silane</p></def></def-item><def-item><term>TREM2</term><def><p>triggering receptor expressed on myeloid cells 2</p></def></def-item><def-item><term>TRITC</term><def><p>tetramethyl-rhodamine
isothiocyanate</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name><article-title>Role of neuroinflammation
in neurodegeneration development</article-title><source>Signal Transduction
Targeted Ther.</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>267</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01486-5</pub-id><pub-id pub-id-type="pmcid">PMC10336149</pub-id><pub-id pub-id-type="pmid">37433768</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Hansson</surname><given-names>O.</given-names></name><article-title>Biomarkers
for neurodegenerative diseases</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><issue>6</issue><fpage>954</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01382-x</pub-id><pub-id pub-id-type="pmid">34083813</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Sun</surname><given-names>M.-K.</given-names></name><name name-style="western"><surname>Alkon</surname><given-names>D. L.</given-names></name><article-title>Alzheimer&#8217;s
therapeutic development: shifting
neurodegeneration to neuroregeneration</article-title><source>Trends
Pharmacol. Sci.</source><year>2024</year><volume>45</volume><issue>3</issue><fpage>197</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2024.01.012</pub-id><pub-id pub-id-type="pmid">38360510</pub-id><pub-id pub-id-type="pmcid">PMC10939773</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Enciu</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Nicolescu</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Manole</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Mure&#351;anu</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Popescu</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Popescu</surname><given-names>B. O.</given-names></name><article-title>Neuroregeneration in neurodegenerative
disorders</article-title><source>BMC Neurol.</source><year>2011</year><volume>11</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.1186/1471-2377-11-75</pub-id><pub-id pub-id-type="pmid">21699711</pub-id><pub-id pub-id-type="pmcid">PMC3146817</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Demuro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di Martino</surname><given-names>R. M. C.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>A.</given-names></name><article-title>GSK-3&#946;, FYN,
and DYRK1A: Master Regulators in Neurodegenerative Pathways</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><issue>16</issue><fpage>9098</fpage><pub-id pub-id-type="doi">10.3390/ijms22169098</pub-id><pub-id pub-id-type="pmid">34445804</pub-id><pub-id pub-id-type="pmcid">PMC8396491</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Matrone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petrillo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nasso</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ferretti</surname><given-names>G.</given-names></name><article-title>Fyn Tyrosine Kinase
as Harmonizing Factor in Neuronal Functions and Dysfunctions</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><issue>12</issue><fpage>4444</fpage><pub-id pub-id-type="doi">10.3390/ijms21124444</pub-id><pub-id pub-id-type="pmid">32580508</pub-id><pub-id pub-id-type="pmcid">PMC7352836</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Guglietti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sivasankar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corrigan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Collins-Praino</surname><given-names>L. E.</given-names></name><article-title>Fyn Kinase
Activity and Its Role in Neurodegenerative Disease Pathology: a Potential
Universal Target?</article-title><source>Mol. Neurobiol.</source><year>2021</year><volume>58</volume><issue>11</issue><fpage>5986</fpage><lpage>6005</lpage><pub-id pub-id-type="doi">10.1007/s12035-021-02518-3</pub-id><pub-id pub-id-type="pmid">34432266</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Schenone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brullo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Musumeci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Biava</surname><given-names>M.</given-names></name><name name-style="western"><surname>Falchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Botta</surname><given-names>M.</given-names></name><article-title>Fyn kinase in brain
diseases and cancer: the search for inhibitors</article-title><source>Curr. Med. Chem.</source><year>2011</year><volume>18</volume><issue>19</issue><fpage>2921</fpage><lpage>2942</lpage><pub-id pub-id-type="doi">10.2174/092986711796150531</pub-id><pub-id pub-id-type="pmid">21651487</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9a"><label>a</label><name name-style="western"><surname>Briner</surname><given-names>A.</given-names></name><name name-style="western"><surname>G&#246;tz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Polanco</surname><given-names>J. C.</given-names></name><article-title>Fyn Kinase Controls
Tau Aggregation In Vivo</article-title><source>Cell Rep.</source><year>2020</year><volume>32</volume><issue>7</issue><fpage>108045</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108045</pub-id><pub-id pub-id-type="pmid">32814048</pub-id></element-citation><element-citation publication-type="journal" id="cit9b"><label>b</label><name name-style="western"><surname>Nygaard</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Strittmatter</surname><given-names>S. M.</given-names></name><article-title>Fyn kinase
inhibition as a novel therapy for Alzheimer&#8217;s disease</article-title><source>Alzheimers Res. Ther.</source><year>2014</year><volume>6</volume><issue>1</issue><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/alzrt238</pub-id><pub-id pub-id-type="pmid">24495408</pub-id><pub-id pub-id-type="pmcid">PMC3978417</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Marotta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Basagni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rosini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Minarini</surname><given-names>A.</given-names></name><article-title>Role of Fyn Kinase
Inhibitors in Switching Neuroinflammatory Pathways</article-title><source>Curr. Med. Chem.</source><year>2022</year><volume>29</volume><issue>27</issue><fpage>4738</fpage><lpage>4755</lpage><pub-id pub-id-type="doi">10.2174/0929867329666211221153719</pub-id><pub-id pub-id-type="pmid">34939537</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Saminathan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Anantharam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kanthasamy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kanthasamy</surname><given-names>A. G.</given-names></name><article-title>Fyn Kinase-Mediated
PKC&#948; Y311 Phosphorylation Induces Dopaminergic Degeneration
in Cell Culture and Animal Models: Implications for the Identification
of a New Pharmacological Target for Parkinson&#8217;s Disease</article-title><source>Front. Pharmacol</source><year>2021</year><volume>12</volume><fpage>631375</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.631375</pub-id><pub-id pub-id-type="pmid">33995031</pub-id><pub-id pub-id-type="pmcid">PMC8113680</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><article-title>New insights
into glycogen synthase kinase-3: A common target for neurodegenerative
diseases</article-title><source>Biochem. Pharmacol.</source><year>2023</year><volume>218</volume><fpage>115923</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2023.115923</pub-id><pub-id pub-id-type="pmid">37981175</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><article-title>The role of glycogen synthase kinase
3 beta in neurodegenerative diseases</article-title><source>Front.
Mol. Neurosci.</source><year>2023</year><volume>16</volume><fpage>1209703</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2023.1209703</pub-id><pub-id pub-id-type="pmid">37781096</pub-id><pub-id pub-id-type="pmcid">PMC10540228</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Hur</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F. Q.</given-names></name><article-title>GSK3 signalling
in neural development</article-title><source>Nat. Rev. Neurosci.</source><year>2010</year><volume>11</volume><issue>8</issue><fpage>539</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/nrn2870</pub-id><pub-id pub-id-type="pmid">20648061</pub-id><pub-id pub-id-type="pmcid">PMC3533361</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15a"><label>a</label><name name-style="western"><surname>Morales-Garcia</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Luna-Medina</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alonso-Gil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sanz-Sancristobal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palomo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gil</surname><given-names>C.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perez-Castillo</surname><given-names>A.</given-names></name><article-title>Glycogen synthase
kinase 3 inhibition promotes adult hippocampal neurogenesis <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>
</article-title><source>ACS Chem. Neurosci.</source><year>2012</year><volume>3</volume><issue>11</issue><fpage>963</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1021/cn300110c</pub-id><pub-id pub-id-type="pmid">23173075</pub-id><pub-id pub-id-type="pmcid">PMC3503340</pub-id></element-citation><element-citation publication-type="journal" id="cit15b"><label>b</label><name name-style="western"><surname>Palomo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Morales-Garcia</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Soteras</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alonso-Gil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Encinas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campillo</surname><given-names>N. E.</given-names></name><name name-style="western"><surname>Perez-Castillo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gil</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>A.</given-names></name><article-title>5-imino-1,2,4-thiadiazoles:
first small molecules as substrate competitive inhibitors of glycogen
synthase kinase 3</article-title><source>J. Med. Chem.</source><year>2012</year><volume>55</volume><issue>4</issue><fpage>1645</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.1021/jm201463v</pub-id><pub-id pub-id-type="pmid">22257026</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Gianferrara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cescon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grieco</surname><given-names>I.</given-names></name><name name-style="western"><surname>Spalluto</surname><given-names>G.</given-names></name><name name-style="western"><surname>Federico</surname><given-names>S.</given-names></name><article-title>Glycogen Synthase
Kinase 3&#946; Involvement in Neuroinflammation and Neurodegenerative
Diseases</article-title><source>Curr. Med. Chem.</source><year>2022</year><volume>29</volume><issue>27</issue><fpage>4631</fpage><lpage>4697</lpage><pub-id pub-id-type="doi">10.2174/0929867329666220216113517</pub-id><pub-id pub-id-type="pmid">35170406</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Jain</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>A. K.</given-names></name><article-title>GSK-3beta acts upstream
of Fyn kinase in regulation
of nuclear export and degradation of NF-E2 related factor 2</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><issue>22</issue><fpage>16502</fpage><lpage>16510</lpage><pub-id pub-id-type="doi">10.1074/jbc.M611336200</pub-id><pub-id pub-id-type="pmid">17403689</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Kaufman</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>L. T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kostylev</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Jeng</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Gunther</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Nygaard</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Strittmatter</surname><given-names>S. M.</given-names></name><article-title>Fyn inhibition rescues established
memory and synapse loss in Alzheimer mice</article-title><source>Ann.
Neurol.</source><year>2015</year><volume>77</volume><issue>6</issue><fpage>953</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1002/ana.24394</pub-id><pub-id pub-id-type="pmid">25707991</pub-id><pub-id pub-id-type="pmcid">PMC4447598</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19a"><label>a</label><name name-style="western"><surname>Chiodi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ishihara</surname><given-names>Y.</given-names></name><article-title>&#8243;Magic Chloro&#8243;:
Profound Effects of the Chlorine Atom in Drug Discovery</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><issue>8</issue><fpage>5305</fpage><lpage>5331</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c02015</pub-id><pub-id pub-id-type="pmid">37014977</pub-id></element-citation><element-citation publication-type="journal" id="cit19b"><label>b</label><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><article-title>Halogen bond: its role beyond drug-target binding affinity for drug
discovery and development</article-title><source>J. Chem. Inf. Model.</source><year>2014</year><volume>54</volume><issue>1</issue><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1021/ci400539q</pub-id><pub-id pub-id-type="pmid">24372485</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Contestabile</surname><given-names>A.</given-names></name><article-title>Cerebellar
granule cells as a model to study mechanisms of neuronal apoptosis
or survival <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic>
</article-title><source>Cerebellum</source><year>2002</year><volume>1</volume><issue>1</issue><fpage>41</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1080/147342202753203087</pub-id><pub-id pub-id-type="pmid">12879973</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21a"><label>a</label><name name-style="western"><surname>Kim</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Won</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. Y.</given-names></name><article-title>Neuronal loss in
primary long-term cortical culture involves neurodegeneration-like
cell death via calpain and p35 processing, but not developmental apoptosis
or aging</article-title><source>Exp. Mol. Med.</source><year>2007</year><volume>39</volume><issue>1</issue><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/emm.2007.3</pub-id><pub-id pub-id-type="pmid">17334225</pub-id></element-citation><element-citation publication-type="journal" id="cit21b"><label>b</label><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kessler</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Read</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corbeil</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huttner</surname><given-names>W. B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Wechsler-Reya</surname><given-names>R. J.</given-names></name><article-title>Isolation
of neural stem cells from the postnatal cerebellum</article-title><source>Nat. Neurosci.</source><year>2005</year><volume>8</volume><issue>6</issue><fpage>723</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1038/nn1473</pub-id><pub-id pub-id-type="pmid">15908947</pub-id><pub-id pub-id-type="pmcid">PMC2377345</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Jekabsons</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>D. G.</given-names></name><article-title>Bioenergetic analysis of cerebellar granule neurons
undergoing apoptosis by potassium/serum deprivation</article-title><source>Cell Death Differ.</source><year>2006</year><volume>13</volume><issue>9</issue><fpage>1595</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401851</pub-id><pub-id pub-id-type="pmid">16410795</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Ming</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><article-title>Adult neurogenesis in the mammalian brain: significant answers and
significant questions</article-title><source>Neuron</source><year>2011</year><volume>70</volume><issue>4</issue><fpage>687</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.05.001</pub-id><pub-id pub-id-type="pmid">21609825</pub-id><pub-id pub-id-type="pmcid">PMC3106107</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24a"><label>a</label><name name-style="western"><surname>Calvo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schembri-Wismayer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dur&#225;n-Alonso</surname><given-names>M. B.</given-names></name><article-title>Age-Related Neurodegenerative Diseases:
A Stem Cell&#8217;s Perspective</article-title><source>Cells</source><year>2025</year><volume>14</volume><issue>5</issue><fpage>347</fpage><pub-id pub-id-type="doi">10.3390/cells14050347</pub-id><pub-id pub-id-type="pmid">40072076</pub-id><pub-id pub-id-type="pmcid">PMC11898746</pub-id></element-citation><element-citation publication-type="journal" id="cit24b"><label>b</label><name name-style="western"><surname>Culig</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bohr</surname><given-names>V. A.</given-names></name><article-title>Neurogenesis in
aging and age-related neurodegenerative diseases</article-title><source>Ageing Res. Rev.</source><year>2022</year><volume>78</volume><fpage>101636</fpage><pub-id pub-id-type="doi">10.1016/j.arr.2022.101636</pub-id><pub-id pub-id-type="pmid">35490966</pub-id><pub-id pub-id-type="pmcid">PMC9168971</pub-id></element-citation><element-citation publication-type="journal" id="cit24c"><label>c</label><name name-style="western"><surname>Lilienberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ap&#225;ti</surname><given-names>A. &#180;.</given-names></name><name name-style="western"><surname>R&#233;thelyi</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Homolya</surname><given-names>L.</given-names></name><article-title>Microglia modulate proliferation, neurite generation
and differentiation of human neural progenitor cells</article-title><source>Front. Cell Dev. Biol.</source><year>2022</year><volume>10</volume><fpage>997028</fpage><pub-id pub-id-type="doi">10.3389/fcell.2022.997028</pub-id><pub-id pub-id-type="pmid">36313581</pub-id><pub-id pub-id-type="pmcid">PMC9606406</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Uliassi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gandini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perone</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>M. L.</given-names></name><article-title>Neuroregeneration
versus neurodegeneration: toward a paradigm shift in Alzheimer&#8217;s
disease drug discovery</article-title><source>Future Med. Chem.</source><year>2017</year><volume>9</volume><issue>10</issue><fpage>995</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.4155/fmc-2017-0038</pub-id><pub-id pub-id-type="pmid">28632448</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Vieira</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Vasconcellos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goulart</surname><given-names>V. A. M.</given-names></name><name name-style="western"><surname>Parreira</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Kihara</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Ulrich</surname><given-names>H.</given-names></name><name name-style="western"><surname>Resende</surname><given-names>R. R.</given-names></name><article-title>Neural stem cell
differentiation into mature neurons: Mechanisms of regulation and
biotechnological applications</article-title><source>Biotechnol. Adv.</source><year>2018</year><volume>36</volume><issue>7</issue><fpage>1946</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2018.08.002</pub-id><pub-id pub-id-type="pmid">30077716</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27a"><label>a</label><name name-style="western"><surname>Anesti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Magkafa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prantikou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kazanis</surname><given-names>I.</given-names></name><article-title>Divergence between Neuronal and Oligodendroglial Cell
Fate, in Postnatal Brain Neural Stem Cells, Leads to Divergent Properties
in Polymorphic <italic toggle="yes">In Vitro</italic> Assays</article-title><source>Cells</source><year>2022</year><volume>11</volume><issue>11</issue><fpage>1743</fpage><pub-id pub-id-type="doi">10.3390/cells11111743</pub-id><pub-id pub-id-type="pmid">35681436</pub-id><pub-id pub-id-type="pmcid">PMC9179558</pub-id></element-citation><element-citation publication-type="journal" id="cit27b"><label>b</label><name name-style="western"><surname>Lattke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guillemot</surname><given-names>F.</given-names></name><article-title>Understanding astrocyte differentiation:
Clinical relevance, technical challenges, and new opportunities in
the omics era</article-title><source>WIREs Mech. Dis.</source><year>2022</year><volume>14</volume><issue>5</issue><elocation-id>e1557</elocation-id><pub-id pub-id-type="doi">10.1002/wsbm.1557</pub-id><pub-id pub-id-type="pmid">35546493</pub-id><pub-id pub-id-type="pmcid">PMC9539907</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Osterhout</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Wolven</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Resh</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>M. V.</given-names></name><article-title>Morphological
differentiation of oligodendrocytes requires activation of Fyn tyrosine
kinase</article-title><source>J. Cell Biol.</source><year>1999</year><volume>145</volume><issue>6</issue><fpage>1209</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1083/jcb.145.6.1209</pub-id><pub-id pub-id-type="pmid">10366594</pub-id><pub-id pub-id-type="pmcid">PMC2133143</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Azim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Butt</surname><given-names>A. M.</given-names></name><article-title>GSK3&#946; negatively regulates
oligodendrocyte differentiation
and myelination in vivo</article-title><source>Glia</source><year>2011</year><volume>59</volume><issue>4</issue><fpage>540</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1002/glia.21122</pub-id><pub-id pub-id-type="pmid">21319221</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30a"><label>a</label><name name-style="western"><surname>Lee</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B. H.</given-names></name><article-title>Neuroprotective
Effect of Antioxidants in the Brain</article-title><source>Int. J.
Mol. Sci.</source><year>2020</year><volume>21</volume><issue>19</issue><fpage>7152</fpage><pub-id pub-id-type="doi">10.3390/ijms21197152</pub-id><pub-id pub-id-type="pmid">32998277</pub-id><pub-id pub-id-type="pmcid">PMC7582347</pub-id></element-citation><element-citation publication-type="journal" id="cit30b"><label>b</label><name name-style="western"><surname>Sakai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takata</surname><given-names>F.</given-names></name><name name-style="western"><surname>Iwao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yasunaga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dohgu</surname><given-names>S.</given-names></name><article-title>Brain pericytes upregulate
glutamate uptake by astrocytes</article-title><source>IBRO Neurosci.
Rep.</source><year>2025</year><volume>19</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.ibneur.2025.05.017</pub-id><pub-id pub-id-type="pmid">40535312</pub-id><pub-id pub-id-type="pmcid">PMC12175728</pub-id></element-citation><element-citation publication-type="journal" id="cit30c"><label>c</label><name name-style="western"><surname>Abbrescia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Signorile</surname><given-names>G.</given-names></name><name name-style="western"><surname>Valente</surname><given-names>O.</given-names></name><name name-style="western"><surname>Palazzo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cibelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nicchia</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Frigeri</surname><given-names>A.</given-names></name><article-title>Crucial role of Aquaporin-4
extended isoform in brain water Homeostasis and Amyloid-&#946; clearance:
implications for Edema and neurodegenerative diseases</article-title><source>Acta Neuropathol. Commun.</source><year>2024</year><volume>12</volume><issue>1</issue><fpage>159</fpage><pub-id pub-id-type="doi">10.1186/s40478-024-01870-4</pub-id><pub-id pub-id-type="pmid">39385254</pub-id><pub-id pub-id-type="pmcid">PMC11465886</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31a"><label>a</label><name name-style="western"><surname>Chung</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G. X.</given-names></name><name name-style="western"><surname>Stafford</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>C.</given-names></name><name name-style="western"><surname>Joung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Foo</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Barres</surname><given-names>B. A.</given-names></name><article-title>Astrocytes mediate synapse elimination
through MEGF10 and MERTK pathways</article-title><source>Nature</source><year>2013</year><volume>504</volume><issue>7480</issue><fpage>394</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/nature12776</pub-id><pub-id pub-id-type="pmid">24270812</pub-id><pub-id pub-id-type="pmcid">PMC3969024</pub-id></element-citation><element-citation publication-type="journal" id="cit31b"><label>b</label><name name-style="western"><surname>Xiaoying</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiusheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jilin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiayi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dongxin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wengang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xinyue</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuhua</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deshu</surname><given-names>S.</given-names></name><article-title>Resistin-Inhibited
Neural Stem Cell-Derived Astrocyte Differentiation Contributes to
Permeability Destruction of the Blood-Brain Barrier</article-title><source>Neurochem. Res.</source><year>2019</year><volume>44</volume><issue>4</issue><fpage>905</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1007/s11064-019-02726-3</pub-id><pub-id pub-id-type="pmid">30690681</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Kwon</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>S. H.</given-names></name><article-title>Neuroinflammation in neurodegenerative
disorders: the
roles of microglia and astrocytes</article-title><source>Transl. Neurodegener.</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s40035-020-00221-2</pub-id><pub-id pub-id-type="pmid">33239064</pub-id><pub-id pub-id-type="pmcid">PMC7689983</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Kery</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A. P. F.</given-names></name><name name-style="western"><surname>Kirschen</surname><given-names>G. W.</given-names></name><article-title>Genetic
targeting of astrocytes to
combat neurodegenerative disease</article-title><source>Neural Regener.
Res.</source><year>2020</year><volume>15</volume><issue>2</issue><fpage>199</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.265541</pub-id><pub-id pub-id-type="pmcid">PMC6905329</pub-id><pub-id pub-id-type="pmid">31552885</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Pe&#241;a-Altamira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Prati</surname><given-names>F.</given-names></name><name name-style="western"><surname>Massenzio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Virgili</surname><given-names>M.</given-names></name><name name-style="western"><surname>Contestabile</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Monti</surname><given-names>B.</given-names></name><article-title>Changing paradigm to target microglia
in neurodegenerative diseases: from anti-inflammatory strategy to
active immunomodulation</article-title><source>Expert Opin. Ther.
Targets</source><year>2016</year><volume>20</volume><issue>5</issue><fpage>627</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1517/14728222.2016.1121237</pub-id><pub-id pub-id-type="pmid">26568363</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35a"><label>a</label><name name-style="western"><surname>Panicker</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saminathan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harischandra</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kanthasamy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lawana</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anantharam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kanthasamy</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Kanthasamy</surname><given-names>A.</given-names></name><article-title>Fyn Kinase Regulates Microglial Neuroinflammatory
Responses in Cell Culture and Animal Models of Parkinson&#8217;s
Disease</article-title><source>J. Neurosci.</source><year>2015</year><volume>35</volume><issue>27</issue><fpage>10058</fpage><lpage>10077</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0302-15.2015</pub-id><pub-id pub-id-type="pmid">26157004</pub-id><pub-id pub-id-type="pmcid">PMC4495236</pub-id></element-citation><element-citation publication-type="journal" id="cit35b"><label>b</label><name name-style="western"><surname>Prati</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Simone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bisignano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Armirotti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Summa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pizzirani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Scarpelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Andrisano</surname><given-names>V.</given-names></name><name name-style="western"><surname>Perez-Castillo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Massenzio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Polito</surname><given-names>L.</given-names></name><name name-style="western"><surname>Racchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Favia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bottegoni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>A.</given-names></name><article-title>Multitarget drug discovery
for Alzheimer&#8217;s disease: triazinones as BACE-1 and GSK-3&#946;
inhibitors</article-title><source>Angew. Chem., Int. Ed. Engl.</source><year>2015</year><volume>54</volume><issue>5</issue><fpage>1578</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1002/anie.201410456</pub-id><pub-id pub-id-type="pmid">25504761</pub-id></element-citation><element-citation publication-type="journal" id="cit35c"><label>c</label><name name-style="western"><surname>De Simone</surname><given-names>A.</given-names></name><name name-style="western"><surname>La Pietra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Betari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Petragnani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Conte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Daniele</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pietrobono</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petralla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Casadei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Davani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Frabetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Russomanno</surname><given-names>P.</given-names></name><name name-style="western"><surname>Novellino</surname><given-names>E.</given-names></name><name name-style="western"><surname>Montanari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tumiatti</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ballerini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sarno</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nebbioso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Altucci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Monti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Andrisano</surname><given-names>V.</given-names></name><name name-style="western"><surname>Milelli</surname><given-names>A.</given-names></name><article-title>Discovery of the First-in-Class GSK-3&#946;/HDAC
Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer&#8217;s
Disease</article-title><source>ACS Med. Chem. Lett.</source><year>2019</year><volume>10</volume><issue>4</issue><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.8b00507</pub-id><pub-id pub-id-type="pmid">30996781</pub-id><pub-id pub-id-type="pmcid">PMC6466523</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><article-title>The blood-brain barrier: structure,
regulation, and drug delivery</article-title><source>Signal Transduction
Targeted Ther.</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>217</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01481-w</pub-id><pub-id pub-id-type="pmcid">PMC10212980</pub-id><pub-id pub-id-type="pmid">37231000</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37a"><label>a</label><name name-style="western"><surname>Xiong</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><article-title>Strategies for Structural Modification of Small Molecules
to Improve Blood-Brain Barrier Penetration: A Recent Perspective</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><issue>18</issue><fpage>13152</fpage><lpage>13173</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00910</pub-id><pub-id pub-id-type="pmid">34505508</pub-id></element-citation><element-citation publication-type="journal" id="cit37b"><label>b</label><name name-style="western"><surname>Rankovic</surname><given-names>Z.</given-names></name><article-title>CNS drug design: balancing physicochemical properties
for optimal brain exposure</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><issue>6</issue><fpage>2584</fpage><lpage>2608</lpage><pub-id pub-id-type="doi">10.1021/jm501535r</pub-id><pub-id pub-id-type="pmid">25494650</pub-id></element-citation><element-citation publication-type="journal" id="cit37c"><label>c</label><name name-style="western"><surname>Wager</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Verhoest</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Villalobos</surname><given-names>A.</given-names></name><article-title>Central Nervous
System Multiparameter Optimization Desirability: Application in Drug
Discovery</article-title><source>ACS Chem. Neurosci.</source><year>2016</year><volume>7</volume><issue>6</issue><fpage>767</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.6b00029</pub-id><pub-id pub-id-type="pmid">26991242</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mader</surname><given-names>M.</given-names></name><article-title>Brain penetrant kinase
inhibitors: Learning from kinase neuroscience
discovery</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2018</year><volume>28</volume><issue>11</issue><fpage>1981</fpage><lpage>1991</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2018.05.007</pub-id><pub-id pub-id-type="pmid">29752185</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Albertini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petralla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Massenzio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Monti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rizzardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bergamini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Uliassi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chavarria</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fricker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Goettert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kronenberger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gehringer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laufer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>M. L.</given-names></name><article-title>Targeting
Lewy body dementia with neflamapimod-rasagiline hybrids</article-title><source>Arch. Pharm.</source><year>2024</year><volume>357</volume><issue>6</issue><elocation-id>e2300525</elocation-id><pub-id pub-id-type="doi">10.1002/ardp.202300525</pub-id><pub-id pub-id-type="pmid">38412454</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40a"><label>a</label><name name-style="western"><surname>Motaln</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rogelj</surname><given-names>B.</given-names></name><article-title>The Role of c-Abl Tyrosine
Kinase in Brain and Its Pathologies</article-title><source>Cells</source><year>2023</year><volume>12</volume><issue>16</issue><fpage>2041</fpage><pub-id pub-id-type="doi">10.3390/cells12162041</pub-id><pub-id pub-id-type="pmid">37626851</pub-id><pub-id pub-id-type="pmcid">PMC10453230</pub-id></element-citation><element-citation publication-type="journal" id="cit40b"><label>b</label><name name-style="western"><surname>Millar</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Iloputaife</surname><given-names>I.</given-names></name><name name-style="western"><surname>Baldyga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Norling</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Boulougoura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vichos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tchkonia</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deisinger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pirtskhalava</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kirkland</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Travison</surname><given-names>T. G.</given-names></name><name name-style="western"><surname>Lipsitz</surname><given-names>L. A.</given-names></name><article-title>A pilot
study of senolytics to improve cognition and mobility in older adults
at risk for Alzheimer&#8217;s disease</article-title><source>EBioMedicine</source><year>2025</year><volume>113</volume><fpage>105612</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2025.105612</pub-id><pub-id pub-id-type="pmid">40010154</pub-id><pub-id pub-id-type="pmcid">PMC11907475</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41a"><label>a</label><name name-style="western"><surname>Craige</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Reif</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Kant</surname><given-names>S.</given-names></name><article-title>Mixed - Lineage
Protein kinases (MLKs) in inflammation, metabolism, and other disease
states</article-title><source>Biochim. Biophys. Acta</source><year>2016</year><volume>1862</volume><issue>9</issue><fpage>1581</fpage><lpage>1586</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2016.05.022</pub-id><pub-id pub-id-type="pmid">27259981</pub-id></element-citation><element-citation publication-type="journal" id="cit41b"><label>b</label><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Muzaffar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>G.</given-names></name><article-title>Sclareol improves the
pathology of Alzheimer&#8217;s disease by inhibiting microglial inflammation
via interacting with CDK9</article-title><source>Phytomedicine</source><year>2025</year><volume>139</volume><fpage>156504</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2025.156504</pub-id><pub-id pub-id-type="pmid">39970859</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Bandarage</surname><given-names>U.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Come</surname><given-names>J.</given-names></name><name name-style="western"><surname>Court</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marhefka</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nanthakumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Green</surname><given-names>J.</given-names></name><article-title>ROCK inhibitors 3:
Design, synthesis and structure-activity relationships of 7-azaindole-based
Rho kinase (ROCK) inhibitors</article-title><source>Bioorg. Med. Chem.
Lett.</source><year>2018</year><volume>28</volume><issue>15</issue><fpage>2622</fpage><lpage>2626</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2018.06.040</pub-id><pub-id pub-id-type="pmid">30082069</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Cagno</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tintori</surname><given-names>C.</given-names></name><name name-style="western"><surname>Civra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tiberi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Botta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tapparel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lembo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Botta</surname><given-names>M.</given-names></name><article-title>Novel broad spectrum virucidal molecules
against enveloped viruses</article-title><source>PLoS One</source><year>2018</year><volume>13</volume><issue>12</issue><elocation-id>e0208333</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0208333</pub-id><pub-id pub-id-type="pmid">30532192</pub-id><pub-id pub-id-type="pmcid">PMC6285983</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Kinoshita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsubara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishiguro</surname><given-names>H.</given-names></name><name name-style="western"><surname>Okita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tada</surname><given-names>T.</given-names></name><article-title>Structure
of human Fyn kinase domain complexed with staurosporine</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2006</year><volume>346</volume><issue>3</issue><fpage>840</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.05.212</pub-id><pub-id pub-id-type="pmid">16782058</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Buonfiglio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Prati</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bischetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cavarischia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Furlotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ombrato</surname><given-names>R.</given-names></name><article-title>Discovery of Novel
Imidazopyridine
GSK-3&#946; Inhibitors Supported by Computational Approaches</article-title><source>Molecules</source><year>2020</year><volume>25</volume><issue>9</issue><fpage>2163</fpage><pub-id pub-id-type="doi">10.3390/molecules25092163</pub-id><pub-id pub-id-type="pmid">32380735</pub-id><pub-id pub-id-type="pmcid">PMC7248956</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Uliassi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pe&#241;a-Altamira</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Massenzio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Petralla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez
Gonzalez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>M. L.</given-names></name><article-title>A Focused
Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative
Potential</article-title><source>ACS Chem. Neurosci.</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>279</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.8b00242</pub-id><pub-id pub-id-type="pmid">30253086</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Petralla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pe&#241;a-Altamira</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Poeta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Massenzio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Virgili</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barile</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Sbano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Profilo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Corricelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Danese</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giorgi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ostan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Capri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pinton</surname><given-names>P.</given-names></name><name name-style="western"><surname>Palmieri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lasorsa</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Monti</surname><given-names>B.</given-names></name><article-title>Deficiency
of Mitochondrial Aspartate-Glutamate Carrier 1 Leads to
Oligodendrocyte Precursor Cell Proliferation Defects Both <italic toggle="yes">In Vitro</italic> and <italic toggle="yes">In Vivo</italic>
</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><issue>18</issue><fpage>4486</fpage><pub-id pub-id-type="doi">10.3390/ijms20184486</pub-id><pub-id pub-id-type="pmid">31514314</pub-id><pub-id pub-id-type="pmcid">PMC6769484</pub-id></element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Guardigni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Poeta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Santini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tassinari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bergamini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zalambani</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Simone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andrisano</surname><given-names>V.</given-names></name><name name-style="western"><surname>Uliassi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Monti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Fimognari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Milelli</surname><given-names>A.</given-names></name><article-title>Integrating a quinone substructure
into histone deacetylase inhibitors to cope with Alzheimer&#8217;s
disease and cancer</article-title><source>RSC Med. Chem.</source><year>2024</year><volume>15</volume><issue>6</issue><fpage>2045</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.1039/D4MD00175C</pub-id><pub-id pub-id-type="pmid">38911150</pub-id><pub-id pub-id-type="pmcid">PMC11187553</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49a"><label>a</label><name name-style="western"><surname>Weksler</surname><given-names>B.
B.</given-names></name><name name-style="western"><surname>Subileau</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Perri&#232;re</surname><given-names>N.</given-names></name><name name-style="western"><surname>Charneau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Holloway</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leveque</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tricoire-Leignel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nicotra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bourdoulous</surname><given-names>S.</given-names></name><name name-style="western"><surname>Turowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Male</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Roux</surname><given-names>F.</given-names></name><name name-style="western"><surname>Greenwood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>P. O.</given-names></name><article-title>Blood-brain
barrier-specific properties of a human adult brain endothelial cell
line</article-title><source>FASEB J.</source><year>2005</year><volume>19</volume><issue>13</issue><fpage>1872</fpage><lpage>1874</lpage><pub-id pub-id-type="doi">10.1096/fj.04-3458fje</pub-id><pub-id pub-id-type="pmid">16141364</pub-id></element-citation><element-citation publication-type="journal" id="cit49b"><label>b</label><name name-style="western"><surname>Riganti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salaroglio</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Pinz&#242;n-Daza</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Caldera</surname><given-names>V.</given-names></name><name name-style="western"><surname>Campia</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kopecka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mellai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Annovazzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>P. O.</given-names></name><name name-style="western"><surname>Bosia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghigo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schiffer</surname><given-names>D.</given-names></name><article-title>Temozolomide down-regulates P-glycoprotein in human
blood-brain barrier cells by disrupting Wnt3 signaling</article-title><source>Cell. Mol. Life Sci.</source><year>2014</year><volume>71</volume><issue>3</issue><fpage>499</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1007/s00018-013-1397-y</pub-id><pub-id pub-id-type="pmid">23771630</pub-id><pub-id pub-id-type="pmcid">PMC11113102</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Forster</surname><given-names>C.</given-names></name><name name-style="western"><surname>Burek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Weksler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>P. O.</given-names></name><name name-style="western"><surname>Drenckhahn</surname><given-names>D.</given-names></name><article-title>Differential effects of hydrocortisone
and TNF&#945;
on tight junction proteins in an <italic toggle="yes">in vitro</italic> model of
the human blood&#8211;brain barrier</article-title><source>J. Physiol.</source><year>2008</year><volume>586</volume><issue>7</issue><fpage>1937</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2007.146852</pub-id><pub-id pub-id-type="pmid">18258663</pub-id><pub-id pub-id-type="pmcid">PMC2375735</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Rane</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shelar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shinde</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vartak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chotalia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salvi</surname><given-names>R.</given-names></name><article-title>Spectrophotometric
Method for Quantitative Determination of Inulin in Naturolax&#8211;A
Powder</article-title><source>Int. J. Pharma Res. Health Sci.</source><year>2018</year><volume>6</volume><fpage>2160</fpage><lpage>2164</lpage><pub-id pub-id-type="doi">10.21276/ijprhs.2018.01.13</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>